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The early diagnosis of diabetes is 
important in order to avoid long-
term micro- and macrovascular 
complications in individuals at high 
risk of type 2 diabetes. This thesis 
aims to investigate the association 
of various metabolic and genetic 
biomarkers with hyperglycemia 
and type 2 diabetes. Several novel 
biomarkers were identified in this 
study as predictors of hyperglycemia 
and incident type 2 diabetes.
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ABSTRACT 
 
Type 2 diabetes (T2D) is a complex disorder characterized by insulin resistance and pancreatic 
β-cell dysfunction. The incidence and prevalence of T2D have doubled in recent decades, this 
phenomenon being attributable to obesity, sedentary lifestyle and unhealthy diet. Both genetic 
and environmental factors are major determinants of this disease. Genome-wide association 
studies have identified several risk loci for T2D and hyperglycemia, but the biological role of 
most of these variants remains unknown. The early diagnosis of diabetes is important in order 
to avoid long-term micro- and macrovascular complications in individuals at high risk of T2D. 
Therefore, the identification of biomarkers that accurately predict incident T2D is of great 
interest. The main aim of this study was to identify non-genetic and genetic biomarkers that 
would predict hyperglycemia and incident T2D in a prospective follow-up of the population-
based METSIM (METabolic Syndrome In Men) cohort. We also investigated the significance of 
insulin sensitivity and insulin secretion as mediators in the associations of metabolites with the 
deterioration of hyperglycemia and incident T2D. We found that high fasting levels of glycerol, 
free fatty acids, monounsaturated fatty acids (FAs), and saturated FAs, and omega-7 and -9 FAs 
associated with increased risk of the development of hyperglycemia and T2D, whereas high 
levels of omega-6 FAs were associated with reduced risk of hyperglycemia and T2D. Insulin 
resistance explained these associations at least in part. With respect to erythrocyte membrane 
FAs, palmitoleic acid, dihomo-gamma-linolenic acid, and the ratios of 16:1n-7/16:0 and 20:3n-
6/18:2n-6 associated with the worsening of hyperglycemia, whereas the linoleic acid level and 
the ratio of 18:1n-7/16:1n-7 were associated with decreases in the hyperglycemia. Palmitoleic 
acid and the ratio of 16:1n-7/16:0 nominally predicted incident T2D, whereas linoleic acid had 
an opposite association. These associations were largely independent of insulin sensitivity, 
insulin secretion and glucose levels. Finally, high levels of acetoacetate and β-hydroxybutyrate 
predicted the worsening of hyperglycemia, and acetoacetate predicted incident T2D. Impaired 
insulin secretion, but not insulin resistance, explained these associations. One common variant 
rs780094 of the glucokinase regulatory protein gene was significantly associated with β-
hydroxybutyrate levels. In conclusion, this study identified several novel biomarkers predicting 
the worsening of hyperglycemia and incident T2D which could be used in clinical practice. 
 
National Library of Medicine Classification: QU 84, QU 90, WK 810, WK 820, WK 880 
 
Medical Subject Headings: Diabetes Mellitus, Type 2; Biological Markers; Genetics; Metabolomics; Hyperglycemia; 
Insulin; Insulin Resistance; Glycerol; Fatty Acids; Ketone Bodies; Cohort Studies  
VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
 
 
Mahendran, Yuvaraj 
Tyypin 2 diabetesta ennustavat biomarkkerit 
Itä-Suomen yliopisto, terveystieteiden tiedekunta 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 214. 2014. 56 s. 
 
ISBN: 978-952-61-1367-8 (print) 
ISBN: 978-952-61-1368-5 (PDF) 
ISSN: 1798-5706 (print) 
ISSN: 1798-5714ȱ(PDF) 
ISSNL: 1798-5706 
 
TIIVISTELMÄ 
 
Puutteellinen insuliinin eritys ja heikentynyt insuliinin vaikutus kohdekudoksissa 
(insuliiniresistenssi) ovat tärkeimmät tyypin 2 diabeteksen aineenvaihdunnan häiriöt.  Tyypin 2 
diabetes on perinnöllinen sairaus, mutta sen puhkeamiseen tarvitaan geenien lisäksi 
ympäristötekijöitä.  Useita tyypin 2 diabetekseen liittyviä geenejä on löydetty viimeisten 
vuosien aikana, mutta geenien funktio on useimmissa tapauksissa edelleenkin tuntematon.  
Tyypin 2 diabeteksen esiintyvyys on nopeasti lisääntynyt viimeisten vuosikymmenien aikana 
johtuen ylipainon lisääntymisestä, liikunnan vähenemisestä sekä epäterveellisestä 
ruokavaliosta.  Tyypin 2 diabeteksen varhainen diagnoosi on tärkeää, koska tähän sairauteen 
liittyy pitkäaikaiskomplikaatioiden riski.  Tutkimuksen tärkein tavoite oli tyypin 2 diabetesta ja 
hyperglykemiaa ennustavien geneettisten ja ei-geneettisten tekijöiden (biomarkkereiden) 
löytäminen. Aineistona oli METSIM (METabolic Syndrome In Men) –kohortti, johon kuului 
10,197 Kuopiossa ja sen lähikunnissa asuvaa miestä. Kohortin viiden vuoden 
seuruututkimuksessa lisääntynyt glyserolin, vapaiden rasvahappojen, tyydyttyneiden 
rasvahappojen, sekä omega 7- ja omega 9- rasvahappojen pitoisuus ennusti hyperglykemian ja 
tyypin 2 diabeteksen kehittymistä. Omega 6-rasvahappojen lisääntynyt pitoisuus puolestaan 
suojasi hyperglykemian ja tyypin 2 diabeteksen kehittymiseltä, joka johtui osittain 
vaikutuksesta insuliiniherkkyyteen.  Punasolumembraanien rasvahapoista palmitoleiinihapon 
ja dihomo-gamma-linoleenihapon lisääntynyt pitoisuus sekä eripituisten rasvahappojen 
lisääntyneet suhteet (16:1n-7/16:0 ja 20:3n-6/18:2n-6) ennustivat hyperglykemian ja tyypin 2 
diabeteksen riskiä. Lisääntynyt linoleenihapon pitoisuus ja lisääntynyt 18:1n-7/16:1n-7 – suhde 
vähensivät puolestaan hyperglykemian riskiä.  Nämä tulokset olivat riippumattomia 
insuliiniresistenssistä, insuliinin erityksestä ja glukoositasoista. Asetoasetaatin ja β-
hydroksibutyraatin lisääntynyt pitoisuus ennusti hyperglykemian kehittymistä ja 
asetoasetaation lisääntynyt pitoisuus myös tyypin 2 diabetesta johtuen insuliinierityksen 
huononemisesta. GCKR-geenin yleinen polymorfia (rs780094) liittyi merkitsevästi β-
hydroksibutyraatin pitoisuuteen. Yhteenvetona voidaan todeta, että tutkimussarjassa löydettiin 
useita uusia biomarkkereita, jotka ennustavat hyperglykemian ja tyypin 2 diabeteksen riskiä ja 
joita voidaan käyttää myös kliinisessä diagnostiikassa. 
 
Luokitus: QU 84, QU 90, WK 810, WK 820, WK 880 
 
Yleinen suomalainen asiasanasto: aikuistyypin diabetes; markkerit; merkkiaineet; geenit; metabolomiikka; 
hyperglykemia; insuliini; insuliiniresistenssi; glyseroli; rasvahapot; ketoaineet; kohorttitutkimus 
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2 Review of the Literature  
 
2.1 PATHOPHYSIOLOGY OF TYPE 2 DIABETES  
 
The development of T2D is characterized by a progressive deterioration of glucose tolerance 
from normal glucose tolerance to abnormal glucose tolerance and finally to diabetes. T2D is 
diagnosed on the basis of elevated glucose levels and/or HbA1c level. According to the 
American Diabetes Association (ADA) criteria, the diagnosis of diabetes is based on elevated 
fasting plasma glucose (FPG)  (≥ 7.0 mmol/L) or elevated 2-hour plasma glucose (2hPG) level (≥ 
11.1 mmol/L) in an oral glucose tolerance test (OGTT) or elevated HbA1c levels (≥ 6.5 %) (6). 
The two major pathophysiological abnormalities in T2D are impaired β-cell function and 
insulin resistance. 
 
2.1.1 Insulin secretion 
Insulin secretion is a highly dynamic process regulated by complex mechanisms. The pancreatic 
β-cell secretes a peptide hormone, insulin, the only blood glucose-lowering hormone in human 
metabolism. The insulin mRNA is translated as a precursor called proinsulin and inserted into 
the endoplasmic reticulum, and further processed to the biological active form inside secretory 
granules. Several intracellular signals, such as Ca2+, ATP, cAMP, and diacylglycerol and inositol 
1,4,5-triphosphate are involved in insulin secretion. Glucose is transported into the β-cells by 
GLUT1 (encoded by SLC2A1) and GLUT3 (encoded by SLC2A3) transporters (7). Upon 
transportation, an increase in glucose metabolism in the β-cell occurs. This involves an 
enhancement in the activity of glucokinase and generates a high concentration of the 
intracellular adenosine triphosphate/adenosine diphosphate (ATP/ADP) ratio. The resulting 
increase in the ATP/ADP ratio triggers the closure of the ATP-sensitive K+ (KATP) channels and 
depolarizes the cell membrane. The activation of  voltage-dependent Ca2+ channels causes an 
increase in Ca2+ entry into the β-cells, and the rise in intracellular Ca2+ concentration ([Ca2+]i)  
which in turn stimulates insulin release (Figure 1) (8). 
Insulin secretion in response to glucose exhibits a characteristic biphasic pattern, this consists of 
a rapid initiated and transient first phase followed by a sustained second phase during which 
insulin secretion continues at a somewhat lower rate but is still enhanced (9). Only a fraction of 
the β-cell insulin content is released during stimulation. The complete loss of the first phase 
insulin secretion and a marked reduction of the second phase insulin release in non-diabetic 
individuals are the early markers for the risk of T2D (10). 
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Figure 1. Regulation of insulin secretion (8). VDCC, voltage-dependent calcium channel; PIP2, 
phosphatidylinositol 4,5-bisphosphate.  
Impaired insulin secretion is the major abnormality encountered in the pathogenesis of T2D. 
One consequence of the decline of early phase insulin secretion is impaired glucose tolerance, 
which leads to the development of post-prandial hyperglycemia which in turn impairs insulin 
secretion via glucotoxicity. Finally, the impairment of insulin secretion causes overproduction of 
endogenous glucose and this ultimately leads to the development of frank diabetes. Early phase 
insulin secretion is impaired in individuals with disturbed glucose homeostasis and in those at 
high risk for T2D. Impaired insulin secretion predicts T2D independent of insulin resistance in 
normoglycemic subjects (11). Defects in insulin secretion are attributable to a decrease in the 
sensitivity of the glucose receptor which transmits the glucose signal to trigger insulin release in 
the pancreatic β-cell (12). Genetic and environmental factors are the main determinants of 
insulin secretion. The offspring of patients with T2D show a defect in the first-phase insulin 
secretion in addition to insulin resistance (13). High levels of saturated fatty acids (FAs) impair 
insulin secretion and this leads to the deterioration of glucose tolerance (14). 
 
2.1.2 Insulin resistance 
Insulin resistance is defined as a reduction in insulin’s ability to stimulate glucose uptake in 
peripheral insulin sensitive tissues. Insulin mediates its action by binding to the insulin receptor 
(IR) in three major tissues, skeletal muscle, liver and the adipose tissues. The IR undergoes 
autophosphorylation and it enhances tyrosine kinase activity. Activated receptors lead to the 
binding of various scaffold proteins, including the insulin receptor substrates (IRS). This, in 
turn, results in the activation of the insulin signalling pathway, where the phosphorylation of 
IRS proteins leads to their association with the p85 regulatory subunit of phosphatidylinositol 3-
kinase (PI3-K). This results in the activation of p100 catalytic subunit of PI3-K that catalyzes the 
production of phosphoinositol lipids, including phosphatidylinositol 3,4,5-trisphosphates 
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[PI(3,4,5)P3], which further activates the Ser/Thr kinase 3-phosphoinositide-dependent protein 
kinase (PDK)-1. PDK-1 phosphorylates and activates other downstream kinases, including Akt 
and protein kinase C (PKC), which mediates translocation of GLUT4. This series of signals 
stimulates glucose uptake into the cells (Figure 2) (15).  
 
Figure 2. Insulin signaling pathway (15). PI(3,4)P2, phosphatidylinositol (3, 4)-bisphosphate; AKT, 
protein kinase B; GLUT4, glucose transporter type 4.  
Since IRS molecules are key mediators in the insulin signaling pathway, IR-deficient mice 
develops severe diabetes resulting in FA infiltration of the liver and increased production of 
ketone bodies (16). The lack of IRS-1 gene in primary adipocytes of mice showed decreased 
glucose transport and GLUT4 translocation in the membrane (17). GLUT4 is the main insulin-
responsive glucose transporter, and mice deficient of GLUT4 exhibit moderate insulin 
resistance and impaired glucose tolerance but do not develop diabetes. However, the GLUT4 
deficiency resulted in growth retardation, reduced fat tissue, cardiac hypertrophy and 
shortened lifespan (18). Defects in the insulin signaling pathway, such as impaired IRS tyrosine 
phosphorylation and reduced activation of PI 3-kinase/Akt signaling have also been 
demonstrated to be responsible for reduced glucose transport and glucose utilization in skeletal 
muscle and adipocytes (19). 
In addition to the defects in the insulin signaling pathway, genetic predisposition, unhealthy 
diet, physical inactivity, accumulation of lipids in the liver and skeletal muscle contribute to 
insulin resistance. 
2.1.2.1 Skeletal muscle insulin sensitivity 
Glucose uptake into skeletal muscle is insulin dependent, and skeletal muscle accounts for 
about 60-70% of whole body glucose uptake (20). GLUT4-mediated glucose transport into 
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skeletal muscle is essential for the maintenance of normal glucose homeostasis, and it is 
activated by insulin and muscle contraction (21). Muscle specific inactivation of the insulin 
receptor results in severe insulin resistance and glucose intolerance (21). Insulin resistance in 
skeletal muscle is attributable to defects in the insulin signalling pathway, such as IRS-1 and 
PI3-K and Akt activation (22). Individuals with T2D exhibit reduced IR and IRS-1 
phosphorylation and lowered PI3-K activity in skeletal muscle (23, 24). Skeletal muscle insulin 
resistance in genetically predisposed individuals manifests itself as impaired activation of PI3-
K, IRS-1 and AKT (25). 
 
2.1.2.2 Liver insulin sensitivity 
 
Liver accounts for ~30% of whole body insulin-mediated glucose uptake and plays a key role in 
the maintenance of glucose homeostasis. Approximately 85% of glucose produced in the liver is 
derived from glycogen breakdown and gluconeogenesis. Insulin regulates both glycogenolysis 
and gluconeogenesis. Impaired insulin mediated suppression of hepatic glucose production 
leads to increased levels of plasma glucose and contributes to the pathogenesis of T2D. In 
addition, hepatic insulin resistance results in other abnormalities including hyperinsulinemia, 
increased β-cell stress, hyperglycemia, dyslipidemia and increased levels of inflammatory 
factors.  
 
The accumulation of triglycerides (TGs) in the liver is responsible for hepatic insulin resistance 
(26). In the liver, an excess formation of diacylglycerols (DAGs) leads to the activation and 
translocation of PKCε in the membrane and consequently to the inhibition of insulin-stimulated 
insulin receptor kinase phosphorylation of IRS proteins which in turn downregulates the 
downstream insulin-signalling cascade. Intrahepatic accumulation of diacylglycerol mediates 
hepatic insulin resistance (27). It is known that defects in the IRS-1 and IRS-2 insulin receptor 
signalling pathways directly contribute to hyperglycemia and hepatic insulin resistance (28). 
 
2.1.2.3 Adipose tissue insulin sensitivity 
 
Adipose tissue accounts for ~10% of whole body glucose uptake. The primary role of adipose 
tissue is to store free fatty acids (FFAs) and release FFAs to ensure adequate energy level in the 
body. In the fed state, the upregulation of lipoprotein lipase (LPL) in adipose tissue hydrolyses 
chylomicron-associated TGs, and stimulates the uptake of FAs by adipose tissue. In the fasting 
state, FFAs originate almost entirely from the hydrolysis of TGs within adipocytes. Stored TGs 
are rapidly mobilized by the action of the three main lipases in the adipocyte: adipose 
triglyceride lipase (ATGL), hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL). 
HSL catalyzes the first and rate-limiting step in the mobilization of FFAs from adipose tissue 
(29, 30). In adipose tissue, HSL is activated by several hormones such as catecholamines, 
adrenocorticotropic hormone and glucagon via cAMP-dependent protein kinase A and 
inhibited by insulin (31, 32). 
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Insulin is the major regulator of LPL and HSL activity in the adipose tissue. Insulin upregulates 
LPL activity and promotes gene expression of acetyl-CoA carboxylase (ACC) and fatty acid 
synthase (FAS) (33). Additionally, insulin prevents HSL activity in the adipose tissue through 
inhibition of its phosphorylation (34). In insulin resistant conditions, the responses of both LPL 
and HSL activities to insulin are blunted. LPL is associated with increased TG synthesis, and the 
ineffective suppression of HSL-mediated lipolysis in the adipose tissue causes an abnormal 
release of FFAs in plasma (35).  
Adipose tissue releases hormones and cytokines that are involved in glucose metabolism, 
inflammation, and lipid metabolism. In obese subjects, levels of FFAs, TNF-alpha, IL-6, 
plasminogen activator inhibitor type 1 and C-reactive protein (CRP) are significantly increased, 
and the levels of adiponectin are low (36). Adiponectin increases insulin sensitivity by 
stimulating FA oxidation and inhibiting hepatic glucose production (37, 38). In obese 
individuals, the levels of TNF-alpha in the adipose tissue are increased and these contribute to 
insulin resistance (39) by inhibiting the genes involved in insulin signaling and adipocyte 
differentiation including CAAT-enhancer-binding protein-α, PPARG, GLUT4, IRS-1 protein, 
protein kinase B (PKB), adiponectin, and long-chain FA acyl-CoA synthase (38). Adipose tissue 
specific downregulation of GLUT4 can cause insulin resistance and thereby increase the risk of 
developing diabetes (40). Adipocytes from diabetic and insulin resistant individuals exhibit 
reduced GLUT4 translocation, reduced IRS-1 expression, impaired insulin-stimulated PI3-K and 
Akt/PKB (20). Elevated levels of TNF-alpha, combined with the elevation of IL-6, IL-1β, and 
CRP proteins are associated with incident diabetes (41). During fasting state, high levels of FFAs 
in plasma, a subsequent increase in the intake of FA by muscle and FA flux to the liver also 
increases and contributes to hepatic gluconeogenesis and ketogenesis. 
 
2.2 DIETARY FAT AS A RISK FACTOR FOR TYPE 2 DIABETES 
 
Essential FAs, such as omega-3 and omega-6 polyunsaturated FAs, trans-fatty acids, and 
saturated FAs (15:0, 17:0) are considered as reliable FA biomarkers. These FAs are derived only 
from diet and cannot be synthesized endogenously. Other saturated and monounsaturated FAs 
are derived either from the diet or are endogenously synthesized.  The levels of these FAs vary 
considerably from day to day within an individual.  Therefore, they cannot be considered as 
reliable biomarkers of dietary intake (42). The distribution of individual FAs can be measured in 
plasma, cholesterol esters, TGs, phospholipids, erythrocytes, platelets, various lipoprotein sub-
fractions and adipose tissue. 
Type of dietary fat intake might be a more important factor for the risk of diabetes than the total 
dietary fat intake (43). The increased intake of saturated FAs increases LDL cholesterol 
concentration. The replacement of saturated FAs by mono-or polyunsaturated FAs has been 
reported to lower the level of LDL cholesterol and to increase that of HDL cholesterol (44). A 
diet high in saturated FAs worsens insulin resistance (45). Randomized clinical studies have 
demonstrated that low-carbohydrate, low-glycemic index, Mediterranean, and high-protein 
diets can improve glycemic control and increase the HDL cholesterol level (46). In non-diabetic 
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men, a high intake of saturated FAs increases the risk of T2D (47). Similarly, a western diet and 
a high fat intake are also associated with incident T2D (48, 49). 
 
 
2.3 GENETICS OF TYPE 2 DIABETES 
 
T2D is a genetically heterogeneous disease and about 30-70% of the risk can be attributed to 
genetic factors. The pattern of inheritance suggests that multiple genes and different 
combination of genes are involved in T2D.  
 
2.3.1 Heritability of type 2 diabetes 
There is undisputed evidence that T2D is inherited. The prevalence of diabetes varies widely 
across different ethnic groups, due to underlying genes and different frequencies of 
predisposing alleles  (50). T2D aggregates in the families. The concordance of T2D in 
monozygotic twins is ~70% compared with 20-30% in dizygotic twins (4). The risk of 
developing T2D is ~40% in the offspring if one parent has diabetes and 70% if both parents have 
diabetes (51, 52). A prospective study has demonstrated a twofold increased risk of incident 
T2D in subjects with a family history of diabetes (53).  
 
2.4 APPROACH FOR GENETIC STUDIES IN TYPE 2 DIABETES 
 
2.4.1 Linkage and candidate gene approach 
Linkage analysis is undertaken to identify the regions of the genome that harbour genes which 
predispose to different diseases. Linkage analysis requires a large pedigree with many affected 
and unaffected individuals from several consecutive generations in the same homogenous 
population (54). With linkage studies, several loci for T2D have been identified on chromosome 
20q and chromosome 1q (q21 – q23) (55-57). The exploration of chromosome 1q revealed the 
gene encoding transcription factor 7-like 2 (TCF7L2). This locus has been reported to confer the 
strongest effect on the risk of T2D, and this association has been replicated in several ethnic 
groups (58, 59).   
The candidate gene approach focuses on the search for an association between disease and 
variants in or near biologically defined candidate genes which have been chosen based on their 
inferred physiological role in disease, especially in pathways involved in insulin secretion and 
insulin resistance. PPARG, KCNJ11, WFS1, HNF1B genes have been identified as risk genes for 
T2D using the candidate gene approach (60).  
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2.4.2 Genome wide association studies   
 
Genome wide association studies (GWAs) are designed to find loci that fit the common disease-
common variant hypothesis of human disease.  This approach is unbiased with respect to the 
genome structure and previous knowledge of the disease etiology. The completion of the 
Human Genome Project in 2003 and the International HapMap Project in 2005 led to the 
identification of several million SNPs.  
 
The first GWAs identified a zinc transporter and member of solute carrier family, SLC30A8, and 
HHEX as the first confirmed candidate genes for T2D and confirmed the association of TCF7L2 
and KCNJ11 with T2D (61). These results provided evidence that the GWA approach was useful 
for identifying functionally relevant loci. Another three GWAs studies identified CDKAL1, 
IGF2BP2, and a variant near CDKN2A-B as novel T2D loci and confirmed the known T2D loci of 
TCF7L2, KCNJ11, PPARG, SLC30A8, and HHEX (62-64).  The association of FTO with T2D was 
identified and subsequently confirmed in replication studies (65, 66). Additionally, meta-
analyses have found six new loci JAZF1, CDC123, TSPAN8, THADA, ADAMTS9, and NOTCH2 
for T2D (67). Most of the T2D loci identified with GWAs were common variants conferring 
small effects. 
 
2.4.3 Exome wide association studies 
 
The exome sequencing approach is based on a common disease-rare variant hypothesis. It 
postulates that multiple rare variants with large effects sizes are the main determinants of 
heritability of the disease. Exome sequencing has been successful in the identification of 
mutations for rare Mendelian disorders (68). A few studies have demonstrated the benefit of 
applying large-scale exome sequencing approach for discovering variations associated with 
complex metabolic traits (69, 70). A recent study in Finnish individuals using the exome chip 
approach identified three new low-frequency loci in TBC1D30, KANK1, and PAM that were 
associated with insulin processing or insulin secretion (71). This study provided the first proof 
that exome-wide association studies are a powerful way for identifying low-frequency 
functional variants for complex diseases.  
 
 
2.5 HYPERGLYCEMIA AND TYPE 2 DIABETES RISK LOCI IDENTIFIED BY 
GWAs 
Altogether GWAs have identified >65 genetic variants associated with T2D (51). Figure 3 
illustrates the year of discovery of all 65 loci associated with T2D and their effect sizes.  
However, for several of these variants, the biological role of the specific variant is unknown. 
Most of the common gene variants of T2D have been associated with β-cell function and not 
with insulin sensitivity (72).   
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Figure 3. 65 T2D variants identified with GWAs (modified from ()), the red rectangle represents 
genetic loci that are associated with both fasting glucose and T2D. 
So far GWAs have reported 36 variants associated with fasting glucose levels (73-75), but the 
association of these variants with T2D has remained unclear. For example, GCK, MTN1RB and 
G6PC2 are associated with fasting glucose with strong effect sizes, but they do not have any 
significant effects on the risk of T2D. In contrast, TCF7L2 is the strongest candidate gene for 
T2D, but its effect on fasting glucose level is limited.  Individual SNPs associated with 
hyperglycemia and T2D are summarized in detail in Table 1.  Only the most important genes 
regulating the risk of T2D and hyperglycemia are discussed below. 
 
2.5.1 Gene variants affecting insulin secretion 
ARAP1 also known as CENTD2 encodes ArfGAP with RhoGAP domain, ankyrin repeat and 
PH domain 1. ARAP1 gene is known to regulate EGF-R trafficking and the signaling also 
involved in apoptosis (76, 77). The variant rs1552224 in ARAP1 is associated with an increased 
risk of T2D and decreased glucose-stimulated insulin release (78, 79). 
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Table 1. Single nucleotide polymorphisms associated with T2D, insulin secretion, insulin sensitivity, 
obesity and other glycemic traits 
Gene SNP 
Chromosomal 
Location 
GWA 
trait 
Other reported associations with 
phenotypes 
References 
Gene variants affecting insulin secretion 
 ADCY5 rs11708067 3q21.1 FG, T2D Decreased HOMA-B 
Decreased birth weight 
(73) 
(80) 
 ADRA2A rs10885122 10q25.2 FG  (81) 
 ARAP1/ 
CENTD2 
rs1552224 11q13.4 T2D  (79) 
BCL11A rs10490072 2p21 T2D  (82) 
CDKAL1 rs7754840 6p22.3 T2D Impaired conversion of  
proinsulin to insulin 
Decreased birth weight 
(83-85) 
 
(86) 
CDKN2A/B  rs10811661 9p21 T2D   (87) 
C2CD4A rs7172432 15q22.2 T2D  (88) 
C2CD4B rs11071657 15q22.2 FG Decreased HOMA-B (73, 81) 
DGKB rs2191349 7p21.2 FG, T2D Decreased HOMA-B  (73, 81) 
FADS1 rs174550 11q12.2-q13.1 FG Decreased HOMA-B  (73, 81) 
GCK rs4607517 
rs1799884 
7p15.3-p15.1 FG, T2D 
FG, T2D 
Decreased HOMA-B  
 
(73, 81) 
 
G6PC2 rs560887 2q24.3 FG Decreased HOMA-B 
Decreased T2D risk 
(73, 81) 
 
GLIS3 rs7034200 9p24.2 FG Decreased HOMA-B  (73, 81) 
HMGA2 rs1531343 12q15 T2D  (78) 
HNF1A/ 
TCF1 
rs7957197 12q24.31 T2D  (78) 
HNF1B rs7501939 17q12 T2D  (84)(89) 
HHEX rs1111875 10q23.33 T2D Decreased birth weight (86, 87, 90) 
IGF2BP2 rs4402960 3q27.2 T2D  (63, 87, 91-93) 
JAZF1 rs864745 7p15 T2D  (67, 94) 
KCNJ11 rs5219 11p15.1 T2D Increased glucagon level (92, 95, 96) 
KCNQ1 rs2237895 11p15 T2D  (97, 98) 
KLF14 rs972283 7q32 T2D  (78) 
MTNR1B rs10830963 11q21–q22 FG, T2D  (92, 99) 
MADD rs7944584 11p11.1 FG Impaired proinsulin to insulin conversion  
Decreased HOMA-B 
(100) 
 
(73) 
PROX1 rs340874 1q41 FG, T2D Decreased Insulin sensitivity  
Decreased HOMA-B 
(73, 81) 
PRC1 rs8042680 15q26.1 T2D  (78) 
SLC30A8 rs13266634 8q12.11 FG, T2D Impaired proinsulin to insulin conversion (61, 83, 101, 
102) 
SLC2A2 rs11920090 3q26.1-q26.2 T2D Decreased HOMA-B  (73) 
TP53INP1 rs896854 8q22 T2D  (78) 
TCF7L2 rs7903146 10q25.3 FG, T2D Impaired proinsulin to insulin conversion 
Decreased incretin effect 
Decreased glucagon level 
(58, 83, 102, 
103) 
 
(104) 
ZBED3 rs4457053 5q13.3 T2D  (78) 
ZFAND6 rs11634397 15q25.1 T2D  (78) 
Gene variants affecting insulin sensitivity 
GCKR rs780094 2p23 FG, T2D, 
FI, TGs 
 (73, 102) 
IRS1 rs2943641 2q36 T2D  (105) 
PPARG 
 
rs1801282 3p25 T2D  (106) 
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Gene variants affecting obesity 
FTO rs9939609 16q12.2 BMI,T2D Decreased insulin sensitivity 
Increased fasting insulin 
(66, 78) 
Gene variants with unknown function 
ADAMTS9 rs4607103 3p14.3-2 T2D Decreased insulin sensitivity 
Increased insulin secretion 
(107) 
ANKRD55 rs459193 5q11.2 T2D Decreased insulin sensitivity (108) 
ANK1 rs516946 8p11.1 T2D Decreased insulin secretion (108) 
AP3S2  rs2028299 15q26.1 T2D, BMI  (109, 110) 
BCAR1  rs7202877 16q23.1 T2D Decreased disposition index (108) 
CCND2  rs11063069 12p13 T2D  (111) 
CDC123D/ 
CAMK1D 
rs12779790 10p13 T2D Decreased insulin secretion 
Decreased arginine stimulated  
insulin secretion 
(82, 94) 
CLIP2 rs10401969 19p13.11 T2D, TGs, 
LDL 
 (111) 
CRY2 rs11605924 11p11.2 FG, T2D  (73) 
DUSP8  rs5945326 11p15.5 T2D  (78) 
GCC1 rs6467136 7q32.1 T2D  (112) 
GIPR rs10423928 19q13.3 2hPG, T2D Decreased insulin secretion 
Increased fasting proinsulin 
(75) 
(102) 
GLIS3 rs7034200 9p24.2 FG, T2D,  Decreased HOMA-B 
Decreased fasting insulin 
Decreased insulin secretion 
(73) 
 
(81) 
GRB14  rs13389219 2q22-q24 T2D Decreased Matsuda ISI 
Increased HOMA-B 
Increased fasting insulin 
(108) 
HMG20A  rs7178572 15q24 FG, T2D, 
BMI 
 (110) 
HNF4A rs4812829 20q13.12 T2D Decreased β-cell function (110) 
KLHDC5  rs10842994 12p11.22 T2D  (111) 
KCNK16  rs1535500 6p21.2-p21.1 T2D  (112) 
MAEA rs6815464 4p16.3 T2D  (112) 
MC4R  rs12970134 18q22 T2D, TGs, 
BMI 
Increased insulin resistance (108, 111) 
NOTCH2  rs10923931 1p13-p11 T2D Decreased fasting insulin (113) 
PEPD rs3786897 19q13.11 T2D  (112) 
PSMD6 rs831571 3p14.1 T2D  (112) 
PTPRD rs17584499 9p23-p24.3 T2D  (114) 
RBMS1 rs7593730 2q24.2 T2D Decreased HOMA-IR (115) 
SPRY2 rs1359790 13q31.1 T2D  (116) 
SRR rs391300 17p13.3 T2D  (114) 
ST6GAL1 rs16861329 3q27-q28 T2D, TGs, 
HDL-C  
Decreased β-cell function (110, 117) 
TLE1 rs2796441 9q21.32 T2D  (78) 
TLE4 rs13292136 9q21.32 T2D  (111) 
TSPAN8 rs7961581 12q14.1-q21.1 T2D Decreased insulin secretion (94) 
THADA rs7578597 2p21 T2D Decreased insulin secretion (92) 
UBE2E2 rs7612463 3p24.2 T2D Decreased HOMA-B (118) 
VPS26A rs1802295 10q21.1 T2D  (110) 
WFS1 rs10010131 4p16.1 FG, T2D, 
HbA1c 
Decreased insulin secretion (53, 119, 120) 
ZFAND3 rs9470794 15q25.1 T2D  (112) 
ZMIZ1 rs12571751 10q22.3 2hPG, T2D  (108, 111) 
 
FG, Fasting glucose; FI, Fasting insulin; 2hPG, 2 hour postprandial glucose; BMI, Body mass 
index; LDL, low density lipoprotein; HDL-C, High density lipoprotein-cholesterol; TGs; Triglycerides   
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CDKAL1 encodes a cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1. It 
is expressed in pancreatic islets, skeletal muscle and brain (63, 65). Pancreatic β-cell specific 
knockout of CDKAL1 in mice displayed pancreatic islet hypertrophy, a reduction in insulin 
secretion, and impaired blood glucose control (121). Stančáková et al. reported that CDKAL1 
variant rs7754840 was associated with reduced first phase insulin secretion (84). GWAs and 
meta-analysis have revealed significant associations of CDKAL1 variant rs7754840 with T2D in 
various ethnic groups (85, 122). 
DGKB encodes diacylglycerol kinase beta (DGK) and it belongs to the intracellular lipid kinase 
family. DGK phosphorylates diacylglycerol to produce phosphatidic acid (PA), where PA 
regulates PKC. Activation of PKC leads to increased serine phosphorylation of the IRS-1 and 
this subsequently resulted in decreased insulin-stimulated glucose transport activity (123). The 
variant rs2191349 in DGKB was associated with decreased insulin secretion, increased fasting 
glucose and risk of T2D (73). 
FADS1 encodes the fatty acid deta-5 desaturase (D5D), a key enzyme involved in the 
metabolism of long-chain polyunsaturated omega-3 and omega-6 FAs. The D5D enzyme is 
expressed mainly in the liver, brain, heart and lung (1). The SNP rs174548 was found to be 
associated with FADS1 mRNA expression in the liver and rs174550 with low insulin secretion 
(73, 102), fasting glucose, insulin, HOMA-IR, HOMA-B, TGs and T2D (73). 
HHEX encodes the transcription factor hematopoietically expressed homeobox protein which is 
essential for pancreatic and liver development and is also involved in the Wnt signaling 
pathway (124, 125). The variant rs1111875 in the 3’flanking region of HHEX has been associated 
with T2D risk and pancreatic β-cell dysfunction (87, 90). 
IGF2BP2 encoding insulin-like growth factor II mRNA–binding protein 2, plays an important 
role in embryogenesis and pancreatic development (126). IGF2BP2 belongs to a family of 
mRNA-binding proteins (IMP1, IMP2, and IMP3) and regulates the translation of IGF2 mRNA-
binding protein family. This family is known to play a vital role in growth and insulin-signaling 
(127). A common variant rs4402960 in intron 2 of IGF2BP2 has been associated with reduced 
early phase insulin secretion, impaired pancreatic β-cell function and an increased risk of T2D 
(63, 87, 91-93). 
KCNJ11 encodes the potassium inwardly-rectifying channel, subfamily J, member 11 gene.  It 
encodes protein KATP (Kir 6.2) and is highly expressed in the liver. Mutations in KCNJ11 
influence the KATP channel activity and impair insulin secretion in β-cells (128). A KCNJ11 E23K 
(rs5219) variant was found to be associated with an increased risk of T2D, BMI and impaired 
glucose-induced insulin secretion (95). 
KCNQ1 encoding potassium voltage-gated channel, KQT-like subfamily member 1 gene, is 
expressed in the heart, pancreas, kidneys and intestine (97, 129). The encoded protein plays a 
role in the electrical depolarization of the cell membrane in the heart and possibly also in 
pancreatic β-cells (130). Variants rs2283228 and rs2237895 of KCNQ1 have been associated with 
T2D in Asian and European individuals (129).  
13 
 
 
 
MTNR1B encodes the melatonin receptor type 1B. The circadian rhythm of melatonin hormone 
influences insulin secretion and glucose homeostasis through its islet-specific receptor (131). 
The T allele of rs1387153 has been shown to be associated with increased FPG level and an 
increased risk of T2D (99, 132). The risk G allele of SNP rs10830963 has been associated with 
impaired insulin secretion (99). Exome sequencing has revealed that 36 rare variants (minor 
allele frequency < 0.1) of this gene were associated with T2D (133). 
SLC30A8 encodes solute carrier family 30 (zinc transporter), member 8. It is highly expressed in 
the pancreatic islet β-cells (134). Deletion of SLC30A8 exon 3 in mice has resulted in marked 
reduction of the zinc content in islets, reduced fasting insulin and impaired insulin secretion 
(135). The non-synonymous variant rs13266634 in SLC30A8 causes an arginine to tryptophan 
change (Arg325Trp) and this has been associated with a decrease in the first phase insulin 
release and increased susceptibility for T2D (61, 101).  
TCF7L2 encodes transcription factor 7-like 2. It is a member of the T-cell-specific high-mobility 
group (HMG) box-containing transcription factor, a key component of the Wnt-signaling 
pathway. Depletion of TCF7L2 has resulted in increased β-cell apoptosis, decreased β-cell 
proliferation and glucose-stimulated insulin secretion. Variant rs7903146 in the third intron of 
TCF7L2 has been shown to be significantly associated with low levels of insulin secretion and 
an increased risk of T2D (58, 103).  
 
2.5.2 Gene variants affecting insulin sensitivity 
PPARG encodes for peroxisome proliferator activated receptor gamma, one of the members of 
nuclear hormone regulating transcription factors. It is moderately expressed in skeletal muscle, 
liver, macrophages, brain and highly expressed in adipose tissue (136). PPARG is important for 
adipocyte differentiation and the expression of adipocyte-specific genes. Adipose tissue and 
muscle specific deletion of PPARG resulted in glucose intolerance and progressive insulin 
resistance in the adipose tissue, liver and skeletal muscle (137, 138). The missense variant 
Pro12Ala of PPARG has been associated with the risk of T2D (139, 140).  
IRS1 encodes for insulin receptor substrate 1 and plays a major role in insulin signaling. Variant 
rs2943641, located adjacent to IRS1, has been associated with insulin resistance, 
hyperinsulinemia and T2D (105).  
 
GCKR encodes for glucokinase regulatory protein and plays an important role in whole body 
glucose homeostasis in the liver (141). GCKR inhibits glucokinase (GCK) in competition with 
glucose substrate. A variant rs780094 in GCKR  has been shown to be associated with several 
phenotypes including fasting glucose and insulin level, impaired fasting glucose, insulin 
secretion, reduced HOMA-IR, FFAs, serum TGs and the risk of T2D (62, 73, 142).  
 
2.5.3 Gene variants affecting obesity 
FTO encodes for fat mass and obesity associated gene. FTO is expressed in the hypothalamus, 
liver, muscle, adipose tissue and pancreatic β-cell (143). The rs9939609 variant resides within 
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the first intron of FTO has been shown to be associated with obesity, reduced insulin sensitivity, 
and T2D (66, 78). 
 
2.6 METABOLOMICS 
 
Metabolomics is the study of global metabolite profile in the various cells, tissues, organs or 
biological fluids. It measures the chemical phenotypes that are the net results of genomic, 
transcriptomic and proteomic variability, therefore providing the most integrated profile of 
biological status. Metabolomics is used to discover new diagnostic markers and to enhance 
better understanding of disease mechanisms. 
 
2.6.1 Untargeted metabolomics 
The untargeted metabolomics approach has the ability to detect and quantify a broad range of 
both known and unknown metabolites and reveal potential metabolites linking cellular 
pathways to biological mechanisms. This approach makes it possible to assess a large number 
of metabolites that are substrates and products in different metabolic pathways. Using this 
approach, differences in concentrations of a wide range of metabolite profiles, such as bile acids, 
urea cycle intermediates, purine degradation products, glutamine, glutamate, FFAs, 
acylcarnitines, lysophosphatidylcholines and other small molecules can been measured e.g. 
before and after a glucose load (144, 145). In obese individuals, several metabolites (FFAs, TGs, 
amino acids, C3 and C5 acylcarnitine, glutamate, pyruvate) have been reported to be elevated 
as compared to those of lean subjects indicating that branched-chain amino acids (BCAAs) 
contribute to the development of obesity-associated insulin resistance (146).  
Longitudinal studies have revealed that plasma branched-chain and aromatic amino acids are 
new predictors of the development of T2D (147). A 12-year follow-up study on lipid profiling 
during a 2-hour glucose tolerance test found that TGs of low carbon number and the double 
bond content were associated with an increased risk of T2D. These lipids were elevated in 
insulin resistance whereas TGs of high carbon number and the double bond content were 
poorly correlated with insulin resistance (148). The TwinsUK Study assessed metabolites before 
and after hyperglycemia and identified that glucose, mannose, FFAs, and amino acids (BCAAs, 
valine, isoleucine, leucine, and their branched-chain-keto-acid, 3-methyl-2-oxovalerate, 4-
methyl-2-oxopentanoate and 3-methyl-2-oxobutyrate) were associated with IFG and T2D. 
Adrenate and arachidonate levels were elevated in IFG whereas dodecenoate, heptanoate and 
pelargonate were decreased in subjects with T2D (149). 
 
2.6.2 Targeted metabolomics for biomarker discovery 
Targeted metabolomics has an excellent potential in the identification of new biomarkers as 
well as in the validation of identified biomarkers. By using this approach, specific metabolites 
levels which are chemically characterized and biochemically annotated can be measured by the 
liquid chromatography, nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry. 
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These techniques have their own advantages but some disadvantages in capturing the 
metabolites of interest. In the candidate biomarker discovery study, glycine, 
lysophosphatidylcholine (LPC) (18:2) and acetylcarnitine were found to be significant 
predictors of impaired glucose tolerance and T2D (150). A recent targeted metabolomics study 
reported that sugar metabolites, amino acids and choline-containing phospholipids were 
associated with the risk of T2D (151).  
Glucose, HbA1c and insulin are well known biomarkers for T2D. Recently several new and 
emerging metabolic biomarkers for T2D and glycemia were reported, including ferritin, leptin, 
adiponectin, CRP, interleukin-2 receptor A, interleukin 6, interleukin-18, plasminogen activator 
inhibitor-1, apolipoprotein B, serum γ-glutamyl transferase, plasma fetuin-A, plasma levels of 
E-selectin, intercellular adhesion molecule-1 (ICAM-1), and tissue plasminogen activator (152-
160). A recent longitudinal study has indicated that plasma levels of alanine, leucine, isoleucine, 
tyrosine, and glutamine predict incident T2D (161). Furthermore, the concentration of leucine, 
valine, and phenylalanine predicted insulin resistance (162), and alanine, lactate, and pyruvate 
predicted the levels of 2-hour glucose (163).  
 
2.6.2.1 Glycerol, free fatty acids and fatty acids 
In the 1950’s Gordon, reported that plasma FFAs are mainly released from the adipose tissue 
and are utilized by metabolically active tissues, such as skeletal muscle and liver (164). Glycerol 
and FFAs in the plasma are the two main components released from TGs by lipolysis in the 
adipose tissue (Figure 4). Glycerol acts as a gluconeogenic substrate and thus regulates glucose 
homeostasis. In the fasting state, elevated levels of FFAs almost entirely originate from the 
hydrolysis of TGs in the adipose tissue. The stored TGs are rapidly mobilized by the action of 
the three main lipases of the adipocyte: ATGL, HSL and MGL.  
 
Circulating glycerol and FFAs levels are also regulated by obesity, physical activity, starvation, 
hormonal factors, short- and long term dietary intake and multiple pathological conditions, e.g. 
abnormal glucose tolerance and metabolic syndrome (165, 166). Insulin plays a vital role in 
regulating the levels of glycerol and FFAs by inhibiting lipolysis in the adipose tissue, 
explaining why glycerol and FFA concentrations are reduced after a meal that contains 
carbohydrate, which stimulate insulin secretion. In insulin resistance states, an increased 
amount of lipolysis of stored TG molecules in the adipose tissue produces high amount of 
glycerol and FAs (167, 168). Glycerol is a gluconeogenic substrate and stimulates 
gluconeogenesis (169).  Elevated levels of glycerol and FFAs have been shown to be associated 
with hyperglycemia and T2D (170, 171). A few prospective studies have reported that high 
levels of fasting FFAs and TGs are predictors of incident T2D (172-176).    
 
Polyunsaturated omega-3 and omega-6 fatty acids (PUFAs) are derived from the diet and 
cannot be synthesized de novo in humans. In contrast, monounsaturated omega-7 and omega-9 
fatty acids (MUFAs) are derived from the de novo synthesized saturated FAs. Thus, the serum 
FA profile is determined by both diet and endogenous FA metabolism (42). The serum lipid 
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Figure 4. Metabolic pathways (adapted from richsen.wordpress.com). Glucose 6-P, glucose 6-
phosphate; TCA, tricarboxylic acid cycle; VLDL, very low-density lipoprotein; Acetyl CoA, acetyl 
coenzyme A. 
 
esters reflect the intake of individual FAs over the last few weeks. Endogenously synthesized 
serum FA pattern is mainly influenced by genetic disposition and intrauterine programming 
(177). A high intake of saturated FAs increases the risk of hyperglycemia and T2D (178).  
However, high concentrations of polyunsaturated omega-3 FAs have not predicted the 
lowering of the risk of T2D (179-181). A meta-analysis including 26 studies concluded that 
marine omega-3 FAs (including docosahexaenoic acid, DHA) in the diet did not exert beneficial 
effects on the prevention of T2D, with the exception of benefits for Asian populations (182). 
Omega-3 and omega-6 FAs have been associated with improved insulin sensitivity in 
individuals with T2D. In contrast, saturated FAs have been reported to impair the action of 
insulin (183, 184). Monounsaturated omega-7 and omega-9 FAs have been previously shown to 
increase the risk of T2D (185-187).  
 
2.6.2.2 Erythrocyte membrane fatty acids 
 
The FA composition is predominantly determined by long term dietary FAs intake of the order 
of 120 days and endogenous synthesis of FA. It can be measured in various tissues and lipid 
pools and erythrocyte membrane (188, 189). Membrane phospholipids reflect serum FA profiles 
of saturated and monounsaturated FAs but they may also contain lower levels of omega-3 and 
omega-6 FAs (190). Erythrocyte membrane lacks de novo FA synthesis and modification by 
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desaturation or elongation, and it mirrors long-term FA intake, whereas plasma FAs and TG 
fractions represent dietary intake only of the past few days (191, 192). Delta-6 desaturases (D6D) 
and D5D are required for the synthesis of the highly unsaturated FAs by introducing a double 
bond in the long chain FAs. Stearoyl coenzyme A desaturase (SCD) catalyzes the synthesis of 
monounsaturated FAs (MUFA) from saturated FAs (SFAs) (193).  
 
The FA synthesis pathway produces saturated FAs, which can then be elongated and 
desaturated to generate FAs such as palmitoleic acid, oleic acid, or vaccenic acid. Activities of 
desaturases are difficult to measure directly in large-scale epidemiological studies, and 
therefore as an alternative, enzymatic conversions are estimated by the FA product-to-precursor 
ratios (194). Most of the case-control studies have reported that the levels of individual 
erythrocyte membrane fatty acids (EMFAs), desaturase and elongase activities are elevated in 
individuals with T2D than in control subjects (195-201). Furthermore, prospective studies have 
identified EMFAs and desaturase activities as predictors for incident T2D (181, 202, 203). 
 
2.6.2.3 Ketone bodies 
The two main ketone bodies (KBs), 3-hydroxybutyrate (BHB) and acetoacetate (AcAc) play a 
vital role in serving as a major source of body fuel in the fasting state. The low availability of 
carbohydrates enables fat-derived energy to be generated in the liver which is utilized by many 
organs, such as brain, heart, kidney and skeletal muscle. For instance, after an overnight fast, 
KBs supply 2-6% of the body energy requirement, whereas after a 3-day fast, they supply 30-
40% of energy requirements (204).  
 
During fasting, increased lipolysis in the adipose tissue results in the release of FFAs into the 
plasma (Figure 4). FFAs are degraded through β-oxidation in the liver mitochondria, resulting 
in the production of acetyl-CoA. Acetyl-CoA is then either incorporated into the tricarboxylic 
acid cycle or channeled into the ketogenesis pathway. Ketogenesis takes place in the liver, 
stimulated by an excess FFA availability in the liver. Insulin plays a central role in regulating 
KB levels and inhibiting ketogenesis by triggering dephosphorylation of HSL and hindering the 
breakdown of TGs to FFAs and glycerol. Ketogenesis takes place mainly during a state of 
insulin deficiency and glucagon excess (205, 206). 
 
Abnormal KB levels have been implicated in diabetic ketoacidosis due to the impairment in 
insulin secretion (207, 208). Elevated levels of KBs have been shown to be associated with 
insulin resistance and T2D (209). In contrast, a recent study using a metabolomics approach 
revealed that the levels of KBs were associated with increased insulin sensitivity (210). 
Furthermore, a strong correlation has been found between plasma glucose and FFA with KB 
levels (211). Several small studies reported that KB levels were decreased in obese women 
compared to lean women, and KBs levels were higher in obese individuals with abnormal 
glucose tolerance than in obese individuals with normal glucose tolerance (212, 213). 
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4 Subjects, Materials and Methods 
 
4.1 SUBJECTS 
The original METSIM cohort includes 10,197 Finnish men with varying degrees of glucose 
tolerance at baseline. Subjects included in this study were randomly selected from the 
population register of Kuopio town, Eastern Finland. The cross-sectional Studies I-III included 
only non-diabetic subjects and individuals with newly diagnosed T2D (none of the participants 
were receiving antidiabetic medication) and the follow-up study included only non-diabetic 
individuals at baseline (Figure 5). 
 
 
 
Figure 5. Study subjects 
 
4.1.1 Baseline study 
Studies I & III. The cross-sectional analysis included 9,398 Finnish men from a population-
based METSIM (METabolic Syndrome In Men) study performed during 2005-2010 (age 57±7 
years, BMI, 27.0±4.0 kg/m2, mean ± SD). Characteristics of the subjects included in the baseline 
studies are given in Table 2. Glucose tolerance was classified according to the ADA criteria (6). 
Among participants 3,034 (32.3%) had normal glucose tolerance, NGT; 4,344 (46.2%) had 
isolated impaired fasting glucose, IFG; 312 (3.3%) had isolated impaired glucose tolerance, IGT; 
1,059 (11.3%) had both IFG and IGT, and 649 (6.9%) had newly diagnosed T2D). Individuals 
with previously diagnosed type 1 or type 2 diabetes were excluded from all statistical analyses. 
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Table 2. Characteristics of the participants included in the METSIM study 
Variable 
No of 
Cases Mean ± SD Range 
Age, years 9,398 57.3 ± 7.1 45 - 74 
Body mass index, kg/m2 9,395 27.0 ± 4.0 16.2 - 55.4 
Fasting glucose, mmol/L 9,398 5.8 ± 0.7 3.5 - 20.0 
2h plasma glucose, mmol/L 9,396 6.4  ± 2.4 1.4 - 38.2 
Fasting insulin, pmol/L 9,394 52.3 ± 39.3 6.0 - 611.4 
2h insulin, pmol/L 9,386 334.9 ± 345.8 10.8 - 5191.2 
Matsuda Insulin Sensitivity Index, mg/dL, mU/L 9,337 6.7 ± 4.2 0.5 - 42.5 
Insulin AUC0-30 / Glucose AUC0-30, pmol/mmol 9,343 30.7 ± 21.3 1.95 - 313.3 
Glycerol x 100, mmol/L 9,349 6.1 ± 2.6 0.0 - 27.3 
Fasting free fatty acids x 10, mmol/L 9,395 3.7 ± 1.5 0.6 - 17.8 
Total triglycerides, mmol/L 9,397 1.4 ± 1.0 0.3 - 37.6 
Omega-3 fatty acids, percentage of total FAs 9,285 4.5 ± 1.4 1.5 - 16.3 
Docosahexaenoic acid, percentage of total FAs  9,282 1.9 ± 0.7 0.0 - 6.1 
Omega-6 fatty acids, percentage of total FAs 9,285 32.9 ± 4.3 12.8 - 47.7 
Linoleic acid, percentage of total FAs 9,280 27.9 ± 4.4 8.9 - 42.3 
Monounsaturated fatty acids, percentage of total FAs 9,285 30.3 ± 4.1 11.0 - 53.2 
Saturated fatty acids and omega-7&-9 fatty acids, 
percentage of total FAs 9,285 62.6 ± 4.5 49.5 - 85.3 
Acetoacetate, mmol/L 9,243 0.06 ± 0.04 0.0 - 0.58 
β-hydroxybutyrate, mmol/L 9,307 0.14 ± 0.11 0.0 – 2.67  
SD, standard deviation; AUC, area under the curve; FAs, fatty acid. 
 
Study II.  EMFAs were measured in 1,346 Finnish men (age 55 ± 6years, BMI, 26.5 ± 3.5 kg/m2, 
mean ± SD). A total of 1,346 men for the EMFA analysis were selected randomly with equivocal 
percentages of each glucose category as compared to the original METSIM cohort of 10,197 
men. Baseline characteristics of the study participants are shown by means and SDs (Table 3). 
Glucose tolerance category was classified according to the ADA criteria (6) as follows: 456 
(33.9%) had normal glucose tolerance, NGT; 681 (50.6%) had isolated impaired fasting glucose, 
IIFG; 32 (2.4%) had isolated impaired glucose tolerance, IIGT; 118 (8.8%) had both IFG and IGT, 
and 59 (4.4%) had newly diagnosed T2D. Individuals with previously diagnosed type 1 or type 
2 diabetes at baseline were excluded from this study.  
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Table 3. Clinical and laboratory characteristics of the cross-sectional METSIM cohort 
Variable 
No of 
Cases     Mean ± SD         Range 
Age, years 1,347 54.9 ± 5.7  45 - 70 
BMI, kg/m2 1,346 26.5 ± 3.5  17.4 - 48.1 
Fasting glucose, mmol/L 1,347 5.8 ± 0.6  4.1 - 13.7 
2h-glucose, mmol/L 1,346 6.0 ± 2.1  2.2 - 21.1 
Fasting Insulin, pmol/L 1,346 45.5 ± 31.2  6.6 - 370.8 
2h insulin, pmol/L 1,344 268.7 ± 268.5  19.2 - 2111.4 
Matsuda Insulin Sensitivity Index 1,341 7.5 ± 4.4  0.5 - 27.7 
Insulin AUC0-30 / Glucose AUC0-30, pmol/mmol 1,343 28.1 ± 18.0  2.4 - 166.6 
Disposition index (DI30) 1,341 164.7 ± 72.8  16 - 588.3 
16:0 (palmitic acid), %  1,346 22.5 ± 0.9  19.6 - 25.9 
18:0 (stearic acid), % 1,346 15.5 ± 0.5  13.4 - 17.5 
Total SFAs, % 1,346 46.0 ± 1.0  43.2 - 49 
16:1n-7 (palmitoleic acid), % 1,346 0.4 ± 0.2  0.1 - 1.9 
18:1n-7 (vaccenic acid), % 1,346 1.1 ± 0.1  0.8 - 2.6 
18:1n-9 (oleic acid), % 1,346 11.9 ± 0.8  9.6 - 15.4 
Total MUFAs, % 1,346 19.5 ± 1.0  16.3 - 26.4 
18:2n-6 (linoleic acid), % 1,346 8.3 ± 1.1  4.0 - 12.9 
20:3n-6 (dihomo-gamma-linolenic acid), % 1,346 1.5 ± 0.3  0.8 - 3.2 
20:4n-6 (arachidonic acid), % 1,346 11.9 ± 1.1  8.1 - 15.1 
20:5n-3 (eicosapentaenoic acid), % 1,346 1.5 ± 0.6  0.4 - 4.9 
22:4n-6 (adrenic acid), % 1,346 1.9 ± 0.4  0.6 - 3.5 
22:6n-3 (docosahexaenoic acid), % 1,346 6.2 ± 1.1  2.4 - 10.6 
Total PUFAs, % 1,346 34.5 ± 1.2  27.9 - 38.2 
Ratio (16:1n-7/16:0) (SCD1) 1,346 0.018 ± 0.006  0.007 - 0.078 
Ratio (20:3n-6/18:2n-6) (∆6 desaturase) 1,346 1.7 ± 0.3  1.0 - 3.2 
Ratio (20:4n-6/20:3n-6) (∆5 desaturase) 1,346 8.1 ± 1.6  3.5 - 13.7 
Ratio (18:1n-7/16:1n-7) (elongase) 1,346 3.0 ± 0.9  0.8 - 8.5 
        
SD, standard deviation; AUC, area under the curve; SFA, saturated fatty acid; MUFA, 
monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SCD1, stearoyl coenzyme A 
desaturase 1. 
 
4.1.2 Follow-up study 
Studies I & III. In the period 2010-2013, a total of 4,335 non-diabetic subjects from the original 
METSIM cohort of 10,197 men had been so far re-examined (mean follow-up time of 5 years); 
4,059 were non-diabetic and 276 had newly diagnosed T2D at follow-up. The diagnosis of new 
diabetes was based either on an OGTT at the follow-up study or drug treatment for diabetes 
started between the baseline and follow-up studies. 
Study II. The analysis of the prospective ongoing 5-year follow-up study (between 2010-2013) 
included only men who were non-diabetic at the baseline study. Thus, individuals with 
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previously diagnosed T2D were excluded. A total of 735 non-diabetic individuals with EMFA 
measurements at baseline have so far participated in the follow-up study of whom 705 
remained non-diabetic and 30 developed newly diagnosed T2D (7 of them were diagnosed with 
T2D between the baseline and the follow-up studies and all of them were receiving anti-diabetic 
medication; 23 had newly detected T2D in an OGTT performed at the 5-year follow-up visit).   
All the studies were approved by the Ethics Committee of the University of Eastern Finland and 
Kuopio University Hospital, and were conducted in accordance with the principles of the 
Helsinki Declaration. All study participants provided written informed consent. 
 
4.2 MATERIALS AND METHODS 
Anthropometric measurements 
Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. BMI was 
calculated as weight (kg) divided by height (m) squared. Waist and hip circumference were 
measured to the nearest 0.5 cm. 
Oral glucose tolerance test 
A 2-hr OGTT (75 g of glucose) was performed and samples for plasma glucose and insulin were 
drawn at 0, 30, and 120 min.  
Laboratory measurements 
Plasma glucose was measured by enzymatic hexokinase photometric assay and plasma insulin 
was determined by immunoassay. In Study I, serum total TG levels and FFAs were measured 
by enzymatic colorimetric methods. NMR spectroscopy was used to measure fasting glycerol, 
FFAs and serum FA profile (omega-3 FAs, omega-6 FAs, omega-7 and -9 FAs, saturated FAs, 
total FAs, linoleic acid (LA), other polyunsaturated FAs, docosahexaenoic acid (DHA), and 
monounsaturated FAs, relative to total FAs) (214). The results for FAs are expressed relative to 
total FAs and given as percentages in all tables and figures. In Study II, EMFAs were 
determined as previously described (215), with modifications (216). EMFAs were measured by 
gas chromatography. The proportion of each FA is expressed as mole percentage of total FAs in 
all tables. In Study III, NMR spectroscopy was used to measure fasting levels of acetoacetate 
(AcAc) and β-hydroxybutyrate (BHB) levels (mmol/L) in serum samples. NMR methods have 
been previously described in detail (214).  
Calculations 
The trapezoidal method was used to calculate the glucose and insulin areas under the curve 
(AUC) in an OGTT based on samples collected at 0, 30, and 120 min. The calculation of insulin 
sensitivity (Matsuda ISI), insulin secretion (InsAUC0-30/GlucAUC0-30) and disposition (DI30) 
indices have been previously described (217, 218). In Study II, desaturase and elongase enzyme 
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activities were evaluated as EMFA product to precursor ratios as follows: palmitoleic acid 
16:1n-7/palmitic acid 16:0 as a marker of stearoyl coaenzyme A desaturase 1 (SCD1) activity, 
dihomo-gamma-linolenic acid 20:3n-6/linoleic acid 18:2n-6 as a marker of ∆6 desaturase (D6D) 
activity, arachinodic acid 20:4n-6/20:3n-6 as a marker of ∆5 desaturase (D5D) activity, and 
vaccenic acid 18:1n-7/16:1n-7 as a marker of elongase activity. 
Genotyping  
In Study III, the genotyping of 62 SNPs associated with the risk of T2D or hyperglycemia (63, 
73, 111, 219) was primarily based on Illumina HumanExome-12v1_A Beadchip (71). SNPs that 
were not available from the exome array were genotyped using either the Applied Biosystems 
TaqMan Allelic Discrimination Assay or Sequenom iPlex Gold SBE assay. All SNPs were in 
Hardy-Weinberg equilibrium at the significance level corrected for multiple testing by the 
Bonferroni method (P < 0.0012). 
Gene expression analysis  
In Study III, subcutaneous fat biopsy samples (N = 200) were obtained from a random sample of 
the participants of the METSIM baseline study (age 55.6 ± 4.9 years; BMI 26.6 ± 3.3 kg/m2). Total 
RNA was isolated from these samples using Qiagen miRNeasy Kit. Only high-quality samples 
were used for transcriptional profiling with the Illumina Human HT-12 v3 Expression 
BeadChip.  
Statistical analysis  
Statistical analyses were conducted using SPSS version 19 (SPSS, Chicago, IL). All traits, except 
for age were log-transformed to correct for their skewed distributions. In Studies I-III, glycerol, 
FAs, EMFAs proportions and KBs were compared across the FPG and 2hPG categories using 
the general linear model. The linear regression model was used to evaluate fasting levels of 
glycerol, FAs, EMFAs proportions and KBs measured at baseline as predictors for changes in 
Glucose AUC in an OGTT at the 5 year-follow-up study. Unstandardized effect sizes (B [SE]) 
per copy of the risk alleles of the SNPs investigated were estimated by linear regression 
analysis. Logistic regression analysis was used to assess the association of the levels of glycerol, 
FAs, EMFAs proportions and KBs with incident T2D during the follow-up.  
The thresholds of statistical significance in linear and logistic models were P < 5.5 x 10-3 (Study 
I), P < 2.8 x 10-3 (Study II), P < 4.0 x 10-4 (Study III). P < 0.05 was considered as nominally 
significant in all studies. Statistical power calculation was performed in all studies using 
Bioconductor’s GeneticsDesign package version 1.14. Pearson correlation coefficients for 
adipose tissue mRNA expression levels of major enzymes involved in the synthesis and 
degradation of KBs were calculated with insulin sensitivity and insulin secretion.  
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5 Results  
5.1 GLYCEROL AND FATTY ACIDS IN SERUM PREDICT THE DEVELOPMENT 
OF HYPERGLYCEMIA AND TYPE 2 DIABETES (Study I) 
This study evaluated first the association of glycerol, FFAs and serum FAs in non-diabetic 
individuals (N=8,749) and individuals with newly diagnosed T2D (N=649) in the FPG and 2hPG 
categories in a cross-sectional setting. Secondly, these biomarkers were evaluated as predictors 
for the worsening of hyperglycemia and the conversion to type 2 diabetes among non-diabetic 
individuals at baseline in a 4.5-year follow-up study. 
Glycerol and FFAs across the categories of glucose tolerance at baseline 
Fasting glycerol levels were significantly higher across the FPG (P = 4.5x10-28) and 2hPG (P = 
1.2x10-99) categories. Similarly, fasting FFAs levels were significantly higher across the entire 
range of FPG (P = 4.3x10-51) and 2hPG (P = 2.2x10-217) (Figure 6). 
 
Figure 6. Mean values and their 95% CIs of fasting levels of glycerol (A, B) and FFAs (C, D) across 
the entire range of fasting and 2hPG categories. P values (from ANOVA post hoc tests) indicating 
statistical significance with respect to the reference category (fasting or 2hPG <5.0 mmol/L) are 
coded as follows: *P<0.05, **P<0.01. P values for trends, adjusted for age and BMI, were as 
follows: A) 4.5 x 10-28, B) 1.2 x 10-99, C) 4.3 x 10-51, D) 2.2 x 10-217 
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Serum fatty acids 
The levels of omega-3 FAs were significantly lower across the FPG (P = 1.0x10-3) and 2hPG (P = 
1.9x10-4) categories, however the levels were slightly higher within the NGT category. Levels of 
omega-6 FAs were also lower across the FPG (P = 4.3x10-63) and 2hPG (P = 1.2x10-146) categories 
especially in participants with newly diagnosed diabetes (-20 and -16%, in the FPG and 2hPG 
categories, respectively) (Figure 7).  
Fasting levels of monounsaturated FAs were significantly higher across the FPG (P = 3.9 x 10-41) 
and 2hPG (P = 2.0 x 10-78) categories. Also fasting levels of saturated FAs, and omega-7 and -9 
FAs were significantly higher across the FPG (P = 5.1x10-52) and 2hPG (P = 6.1x10-132) categories 
(Figure 7).  
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Figure 7. Mean values and their 95% CIs of omega-3 FAs of total FAs (A, B), omega-6 FAs (C, D), 
monounsaturated FAs (E, F), and saturated FAs and omega-7 and -9 FAs (G, H) across the entire 
range of fasting and 2hPG categories. P values (from ANOVA post hoc tests) indicating statistical 
significance with respect to the reference category (fasting or 2hPG <5.0 mmol/L) are coded as 
follows: *P<0.05, **P<0.01. P-values for trends, adjusted for age and BMI, were as follows: A) 1.0 
x 10-3, B) 1.9 x 10-4, C) 4.3 x 10-63, D) 1.2 x 10-146, E) 3.9 x 10-41, F) 2.0 x 10-78, G) 5.1 x 10-52, H) 
6.1 x 10-132 
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Glycerol and FAs as predictors for hyperglycemia and incident type 2 diabetes 
During a mean 4.5-year follow-up (range 2.5-6.2 years) a total of 276 from 4,335 men developed 
incident T2D. Fasting levels of glycerol (P = 9.1x10-39), FFAs (P = 4.6x10-42), total TGs (P= 3.4x10-
21), monounsaturated FAs (P = 6.4x10-16), and saturated FAs, and omega-7 and -9 FAs (P= 3.3x10-
26), adjusted for age, BMI, smoking and physical activity, predicted an increase in the Glucose 
AUC (Table 5). In contrast, levels of omega-6 FAs (including LA) were associated significantly 
with lower Glucose AUC at follow-up (P = 1.8x10-26). In the logistic regression analysis, fasting 
levels of glycerol (OR 1.18, 95% CI, 1.12-1.24), FFAs (OR 1.19, 95% CI, 1.10-1.29), total TGs (OR 
1.26, 95% CI, 1.11-1.44), monounsaturated FAs (OR 1.09, 95% CI, 1.06-1.12), and saturated FAs, 
and omega-7 and -9 FAs (OR 1.09, 95% CI, 1.06-1.12) significantly predicted an increase in the 
risk of incident T2D.  In contrast, fasting levels of omega-6 FAs significantly predicted a 
decrease in incident T2D (OR 0.92, 95% CI, 0.89-0.95). Omega-3 FAs (including DHA) did not 
predict changes in Glucose AUC or incident T2D.  
Adjustment for Matsuda ISI slightly weakened most of the associations of glycerol, FFAs, total 
TGs, omega-6 FAs, monounsaturated FAs, saturated and omega-7 and -9 FAs with Glucose 
AUC and incident diabetes (Table 5). In contrast, adjustment for insulin secretion (Insulin AUC0-
30/Glucose AUC0-30) did not have any major effect on these associations. However, adjustment 
for DI30 (Matsuda ISI x Insulin AUC0-30/Glucose AUC0-30) had an effect on all the variables with 
incident T2D but not with Glucose AUC.  
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5.2 ASSOCIATION OF ERYTHROCYTE MEMBRANE FATTY ACIDS WITH 
CHANGES IN GLYCEMIA AND RISK OF TYPE 2 DIABETES (Study II)  
Proportions of EMFAs across different glucose tolerance categories at baseline 
This study investigated the proportions of EMFAs and their ratios across the different glucose 
tolerance categories in non-diabetic individuals (N=1,287) and in individuals with newly 
diagnosed T2D (N=59). In comparison with the NGT reference category, saturated FAs did not 
vary significantly across the glucose tolerance categories. In contrast, age and BMI adjusted 
levels of monounsaturated FAs 16:1n-7 were nominally higher from +2 to +24% (P=0.016) across 
the abnormal glucose tolerance categories. Among the PUFAs 18:2n-6 levels were significantly 
lower (P=3.7x10-8), and 22:4n-6 levels were nominally higher (P= 0.044) across the glucose 
tolerance categories. Among the FA ratio’s, 18:1n-7/16:1n-7 was nominally lower (P= 0.027) and 
16:1n-7/16:0 (P=7.2x10-3) and 20:3 n-6/18:2n-6 (P=3.9x10-3) were nominally higher across the 
glucose tolerance categories. 
Association of EMFAs with insulin secretion and insulin sensitivity in the 5-year follow-up 
study 
Insulin sensitivity 
Palmitic acid (P=4.9x10-4) and vaccenic acid (P=3.7x10-6) were significantly associated with 
increased insulin sensitivity, and dihomo-gamma-linolenic acid (P=6.5x10-6) with decreased 
insulin sensitivity. With respect to the EMFA ratios, 16:1n-7/16:0 (SCD1 activity, P=3.1x10-4) and 
20:3n-6/18:2n-6 (D6D activity, P=1.1x10-7) were significantly associated with reduced insulin 
sensitivity, whereas 20:4n-6/20:3n-6 (D5D activity, P=3.6x10-4) and 18:n-7/16:1n-7 (elongase 
activity, P=1.2x10-5) were significantly associated with increased insulin sensitivity.   
Insulin secretion 
Palmitoleic acid (P=3.9x10-4), and the 16:1n-7/16:0 ratio (SCD1 activity, P=4.3x10-5) were 
significantly associated with decreased insulin secretion (DI30), whereas linoleic acid (P=1.6x10-
4) and the 18:1n-7/16:1n-7 ratio (elongase activity, P=4.3x10-5) were significantly associated with 
increased insulin secretion. 
EMFAs proportions as predictors for hyperglycemia and incident type 2 diabetes 
SFAs did not predict changes in Glucose AUC or in incident T2D (Table 6). The levels of 
palmitoleic acid (P=2.8x10-7), dihomo-gamma-linoleic acid (P=2.3x10-4), the 16:1n-7/16:0 ratio 
(SCD1 activity, P=1.6x10-8) and the 20:3n-6/18:2n-6 ratio (D6D activity, P=9.4x10-7) significantly 
predicted an increase in Glucose AUC at follow-up after the adjustment for confounding 
factors, whereas linoleic acid (P=0.0015), and the 18:1n-7/16:1n-7 ratio (elongase activity, 
P=1.5x10-9) significantly predicted a decrease in Glucose AUC.  Palmitoleic acid (OR 1.35, 95% 
CI, 1.07, 1.69, P=0.010) and the 16:1n-7/16:0 ratio (OR 2.23, 95% CI, 1.29, 3.85, P=0.004) nominally 
increased, and linoleic acid (OR 0.54, 95% CI, 0.35, 0.82, P=0.004) nominally decreased the risk of 
incident diabetes. 
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All statistically significant associations persisted after further adjustment for baseline insulin 
sensitivity, insulin secretion, FPG, 2hPG, or the Glucose AUC.  
T
a
b
le
 6
. 
A
s
s
o
c
ia
ti
o
n
 o
f 
b
a
s
e
li
n
e
 p
ro
p
o
rt
io
n
s
 o
f 
E
M
F
A
s
 w
it
h
 G
lu
c
o
s
e
 A
U
C
 a
n
d
 i
n
c
id
e
n
t 
ty
p
e
 2
 d
ia
b
e
te
s
 a
t 
th
e
 5
-y
e
a
r 
fo
ll
o
w
-u
p
 
 
F
a
tt
y
 a
c
id
 
 
G
lu
c
o
s
e
 A
U
C
 a
t 
fo
ll
o
w
-u
p
 (
N
=
7
2
4
)
 
I
n
c
id
e
n
t 
ty
p
e
 2
 d
ia
b
e
te
s
 (
N
=
3
0
)
 
B
*
 
S
E
*
 
P
*
 
P
†
 
P
§
 
P
‡
 
O
R
 (
9
5
 %
 C
I
)
*
 
P
*
 
P
†
 
P
§
 
P
‡
 
1
6
:0
 (
p
a
lm
it
ic
 a
c
id
),
 %
 
-3
1
6
.2
 
3
0
8
.6
 
0
.2
7
2
 
0
.8
7
4
 
0
.1
2
8
 
0
.7
9
0
 
0
.7
4
 (
0
.4
8
, 
1
.1
2
) 
0
.1
5
2
 
0
.2
3
9
 
0
.0
9
8
 
0
.6
4
9
 
1
8
:0
 (
s
te
a
ri
c
 a
c
id
),
 %
 
4
5
8
.1
 
3
4
5
.9
 
0
.1
6
4
 
0
.4
2
6
 
0
.1
0
3
 
0
.2
9
4
 
1
.2
5
 (
0
.6
3
, 
2
.5
0
) 
0
.5
2
0
 
0
.6
3
8
 
0
.3
9
4
 
0
.6
5
0
 
T
o
ta
l 
S
F
A
s
, 
%
 
9
2
2
.4
 
5
5
8
.0
 
0
.0
8
7
 
0
.0
9
7
 
0
.0
9
8
 
0
.0
7
8
 
0
.9
6
 (
0
.6
6
, 
1
.4
1
) 
0
.8
3
6
 
0
.8
3
4
 
0
.8
5
9
 
0
.8
0
4
 
1
6
:1
n
-7
 (
p
a
lm
it
o
le
ic
 a
c
id
),
 %
 
2
1
6
.1
 
4
1
.4
 
2
.8
x
1
0
-7
 
3
.6
x
1
0
-7
 
4
.7
x
1
0
-7
 
1
.7
x
1
0
-7
 
1
.3
5
 (
1
.0
7
, 
1
.6
9
) 
0
.0
1
0
 
0
.0
1
0
 
0
.0
1
5
 
0
.0
2
8
 
1
8
:1
n
-7
 (
v
a
c
c
e
n
ic
 a
c
id
),
 %
 
-3
4
8
.5
 
1
2
6
.9
 
0
.0
0
4
 
0
.0
5
4
 
1
.0
x
1
0
-3
 
0
.0
1
1
 
0
.9
9
 (
0
.7
1
, 
1
.4
0
) 
0
.9
6
6
 
0
.8
0
9
 
0
.8
1
0
 
0
.5
2
5
 
1
8
:1
n
-9
 (
o
le
ic
 a
c
id
),
 %
 
4
0
.7
 
1
9
4
.2
 
0
.8
2
7
 
0
.4
7
2
 
0
.9
8
8
 
0
.2
3
8
 
0
.9
8
 (
0
.5
9
, 
1
.6
2
) 
0
.9
2
5
 
0
.9
8
8
 
0
.8
7
0
 
0
.7
4
0
 
T
o
ta
l 
M
U
F
A
s
, 
%
 
-1
2
.2
 
2
3
8
.9
 
0
.8
1
4
 
0
.8
7
6
 
0
.7
7
4
 
0
.3
5
0
 
1
.2
6
 (
0
.8
6
, 
1
.8
5
) 
0
.2
3
2
 
0
.1
8
9
 
0
.2
5
9
 
0
.0
9
9
 
1
8
:2
n
-6
 (
li
n
o
le
ic
 a
c
id
),
 %
 
-2
8
4
.0
 
9
7
.2
 
1
.5
x
1
0
-3
 
0
.0
0
8
 
1
.0
x
1
0
-3
 
0
.0
3
6
 
0
.5
4
 (
0
.3
5
, 
0
.8
2
) 
0
.0
0
4
 
0
.0
0
5
 
0
.0
0
4
 
0
.0
1
3
 
2
0
:3
n
-6
 (
d
ih
o
m
o
-g
a
m
m
a
-l
in
o
le
n
ic
 a
c
id
),
 %
 
2
3
8
.7
 
6
7
.6
 
2
.3
x
1
0
-4
 
1
.9
x
1
0
-3
 
4
.7
x
1
0
-5
 
3
.6
x
1
0
-4
 
1
.0
4
 (
0
.9
2
, 
1
.1
8
) 
0
.4
8
5
 
0
.6
3
2
 
0
.3
7
4
 
0
.7
3
3
 
2
0
:4
n
-6
 (
a
ra
c
h
id
o
n
ic
 a
c
id
),
 %
 
8
8
.9
 
1
3
0
.6
 
0
.4
3
6
 
0
.8
4
8
 
0
.4
0
7
 
0
.5
2
9
 
 1
.2
4
 (
0
.8
7
, 
1
.7
7
) 
0
.2
3
5
 
0
.2
9
3
 
0
.1
9
5
 
0
.7
0
6
 
2
0
:5
n
-3
 (
e
ic
o
s
a
p
e
n
ta
e
n
o
ic
 a
c
id
),
 %
 
-3
9
.3
 
3
2
.3
 
0
.2
6
7
 
0
.5
6
3
 
0
.1
8
9
 
0
.4
1
9
 
1
.0
4
 (
0
.5
8
, 
1
.8
7
) 
0
.8
9
8
 
0
.8
1
1
 
0
.9
1
9
 
0
.9
0
3
 
2
2
:4
n
-6
 (
a
d
re
n
ic
 a
c
id
),
 %
 
1
2
5
.9
 
5
0
.7
 
0
.0
1
1
 
0
.0
7
0
 
0
.0
0
4
 
0
.0
8
5
 
1
.0
9
 (
0
.9
9
, 
1
.1
9
) 
0
.0
7
3
 
0
.1
1
2
 
0
.0
4
5
 
0
.1
8
3
 
2
2
:6
n
-3
 (
d
o
c
o
s
a
h
e
x
a
e
n
o
ic
 a
c
id
),
 %
 
-7
4
.1
 
6
4
.8
 
0
.3
0
2
 
0
.2
8
4
 
0
.3
2
8
 
0
.2
8
2
 
1
.0
0
 (
0
.7
1
, 
1
.4
1
) 
0
.9
9
2
 
0
.9
9
1
 
0
.9
7
0
 
0
.9
8
0
 
T
o
ta
l 
P
U
F
A
s
, 
%
 
-4
3
6
.0
 
3
3
0
.1
 
0
.2
2
2
 
0
.1
3
3
 
0
.2
6
0
 
0
.0
2
8
 
0
.8
9
 (
0
.6
6
, 
1
.2
0
) 
0
.4
4
1
 
0
.3
9
4
 
0
.4
4
8
 
0
.1
3
6
 
R
a
ti
o
 (
1
6
:1
n
-7
/1
6
:0
) 
(S
C
D
1
) 
2
5
3
.0
 
4
4
.1
 
1
.6
x
1
0
-8
 
4
.5
x
1
0
-8
 
2
.0
x
1
0
-8
 
2
.4
x
1
0
-7
 
2
.2
3
 (
1
.2
9
, 
3
.8
5
) 
0
.0
0
4
 
0
.0
0
5
 
0
.0
0
6
 
0
.0
2
0
 
R
a
ti
o
 (
2
0
:3
n
-6
/1
8
:2
n
-6
) 
(∆
6
 d
e
s
a
tu
ra
s
e
) 
3
2
4
.1
 
6
9
.3
 
9
.4
x
1
0
-7
 
3
.4
x
1
0
-5
 
9
.9
x
1
0
-8
 
1
.0
x
1
0
-5
 
1
.1
1
 (
0
.9
9
, 
1
.2
3
) 
0
.0
7
0
 
0
.1
1
9
 
0
.0
4
2
 
0
.1
9
1
 
R
a
ti
o
 (
2
0
:4
n
-6
/2
0
:3
n
-6
) 
(∆
5
 d
e
s
a
tu
ra
s
e
) 
-1
6
5
.2
 
5
9
.5
 
0
.0
0
4
 
0
.0
0
9
 
1
.0
x
1
0
-3
 
1
.1
x
1
0
-3
 
0
.9
5
 (
0
.7
5
, 
1
.2
1
) 
0
.6
8
5
 
0
.7
9
1
 
0
.6
0
3
 
0
.7
3
5
 
R
a
ti
o
 (
1
8
:1
n
-7
/1
6
:1
n
-7
) 
(e
lo
n
g
a
s
e
) 
-2
4
8
.1
 
4
0
.7
 
1
.5
x
1
0
-9
 
1
.3
x
1
0
-8
 
8
.9
x
1
0
-1
0
 
2
.2
x
1
0
-8
 
0
.6
3
 (
0
.3
9
, 
1
.0
3
) 
0
.0
6
5
 
0
.0
8
0
 
0
.0
6
7
 
0
.1
9
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S
F
A
, 
s
a
tu
ra
te
d
 f
a
tt
y
 a
c
id
; 
M
U
F
A
, 
m
o
n
o
u
n
s
a
tu
ra
te
d
 f
a
tt
y
 a
c
id
; 
P
U
F
A
, 
p
o
ly
u
n
s
a
tu
ra
te
d
 f
a
tt
y
 a
c
id
; 
S
C
D
1
, 
s
te
a
ro
y
l 
c
o
e
n
z
y
m
e
 A
 d
e
s
a
tu
ra
s
e
 
1
. 
B
 
a
n
d
 
S
E
 
w
e
re
 
o
b
ta
in
e
d
 
fr
o
m
 
m
u
lt
ip
le
 
li
n
e
a
r 
re
g
re
s
s
io
n
. 
O
d
d
s
 
ra
ti
o
s
 
(O
R
) 
a
n
d
 
th
e
ir
 
9
5
%
 
c
o
n
fi
d
e
n
c
e
 
in
te
rv
a
ls
 
w
e
re
 
o
b
ta
in
e
d
 
fr
o
m
 
lo
g
is
ti
c
 
re
g
re
s
s
io
n
 
a
n
a
ly
s
e
s
. 
P
*
, 
a
d
ju
s
te
d
 
fo
r 
a
g
e
, 
B
M
I,
 
s
m
o
k
in
g
 
a
n
d
 
p
h
y
s
ic
a
l 
a
c
ti
v
it
y
. 
P
†
, 
a
d
ju
s
te
d
 
fo
r 
a
g
e
, 
B
M
I,
 
s
m
o
k
in
g
, 
p
h
y
s
ic
a
l 
a
c
ti
v
it
y
 
a
n
d
 
M
a
ts
u
d
a
 
in
s
u
li
n
 
s
e
n
s
it
iv
it
y
 
in
d
e
x
 
(I
S
I)
. 
P
§
, 
a
d
ju
s
te
d
 
fo
r 
a
g
e
, 
B
M
I,
 
s
m
o
k
in
g
, 
p
h
y
s
ic
a
l 
a
c
ti
v
it
y
 
a
n
d
 
In
s
u
li
n
 
A
U
C
0
-3
0
/G
lu
c
o
s
e
 
A
U
C
0
-3
0
. 
P
‡
, 
a
d
ju
s
te
d
 f
o
r 
a
g
e
, 
B
M
I,
 s
m
o
k
in
g
, 
p
h
y
s
ic
a
l 
a
c
ti
v
it
y
 a
n
d
 D
I3
0
 (
M
a
ts
u
d
a
 I
S
I 
x
 I
n
s
u
li
n
 A
U
C
0
-3
0
/G
lu
c
o
s
e
 A
U
C
0
-3
0
).
 P
 <
2
.8
x
1
0
-3
 w
a
s
 
c
o
n
s
id
e
re
d
 a
s
 s
ta
ti
s
ti
c
a
ll
y
 s
ig
n
if
ic
a
n
t 
g
iv
e
n
 t
h
e
 1
8
 t
ra
it
s
 t
e
s
te
d
. 
S
ta
ti
s
ti
c
a
ll
y
 s
ig
n
if
ic
a
n
t 
re
s
u
lt
s
 a
re
 m
a
rk
e
d
 i
n
 b
o
ld
. 
 
32 
 
33 
 
5.3 ASSOCIATION OF KETONE BODY LEVELS WITH HYPERGLYCEMIA AND 
TYPE 2 DIABETES (Study III) 
Levels of KBs across the categories of glucose tolerance at the baseline study  
This study examined the association of AcAc and BHB, in non-diabetic individuals (N=8,749) 
and individuals with newly diagnosed T2D (N=649) in the FPG and 2hPG categories (Figure 8). 
In the FPG category, AcAc levels were significantly lower (P < 0.01) in individuals with IFG and 
significantly higher (P < 0.01) in individuals with newly detected diabetes. In the 2hPG 
category, AcAc levels were significantly higher (P < 0.01) in subjects with IGT as well as in 
newly diagnosed diabetes as compared with the reference category. 
 
Figure 8. Mean values and their 95% confidence intervals of fasting levels of AcAc (A, B) and BHB  
(C, D) across the fasting and 2hPG categories. P values (from ANOVA post-hoctests) indi-  
cate statistical significance with respect to the reference category (FPG ≤5.4 mmol/L, 2hPG  
≤5.9 mmol/L). *P<0.05, **P<0.01  
In the FPG category, BHB levels were significantly lower (P < 0.01) in subjects with IFG and 
significantly higher (P < 0.01) in the diabetic range. Considering 2hPG, BHB levels were 
nominally higher in IGT (P < 0.05) and in newly diagnosed T2D (P < 0.01), as compared with the 
reference category.  
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KBs as predictors for hyperglycemia and incident type 2 diabetes 
Follow-up data of 4,335 participants were available from the ongoing prospective METSIM 5-
year follow-up study. A total of 276 participants developed incident diabetes between the 
baseline and follow-up studies. AcAc and BHB levels adjusted for confounding factors known 
to increase the risk of diabetes (age, BMI, smoking, and physical activity) predicted an increase 
in the Glucose AUC evaluated as a continuous variable at follow-up (P=2.3×10-4, P=5.7×10-6, 
respectively (Table 7).  
Table 7. Association of baseline levels of acetoacetate and β-hydroxybutyrate as predictors of 
Glucose AUC and with incident type 2 diabetes at 5-year follow-up. Statistical analyses were 
performed with Glucose AUC as a continuous variable and as the highest quartile (Q4) vs. the three 
lowest quartiles (Q1-Q3) combined and type 2 diabetes as a categorical variable (yes/no) 
Glucose AUC at follow-up as a 
continuous variable 
B SE P* P† P§ 
Acetoacetate, mmol/L 39.5 10.1 2.3x10-4 9.9x10-7 9.3x10-4 
β-hydroxybutyrate, mmol/L 51.6 11.1 5.7x10-6 2.7x10-9 6.2x10-5 
Glucose AUC at follow-up as a 
categorical variable (Q4 vs. Q1-Q3) 
OR 95% CI P* P† P§ 
Acetoacetate, mmol/L 1.56 1.33-1.84 7.9x10-8 9.1x10-11 5.5x10-7 
β-hydroxybutyrate, mmol/L 1.46 1.25-1.72 3.4x10-6 2.1x10-8 1.8x10-5 
No diabetes vs. Newly diagnosed 
type 2 diabetes 
OR 95% CI P* P† P§ 
Acetoacetate, mmol/L 1.32 1.00-1.74 0.047 0.012 0.125 
β-hydroxybutyrate, mmol/L 1.03 0.77-1.36 0.864 0.085 0.345 
 
B and SE were obtained from multiple linear regression. Odds ratios (OR) and their 95% confidence 
intervals were obtained from logistic regression analyses. P*, adjusted for age, BMI, smoking, and 
physical activity. P†, adjustment for age, BMI, smoking, physical activity and Matsuda ISI. P§, 
adjustment for age, BMI, smoking, physical activity and InsAUC0-30/GlucAUC0-30 .Statistically 
significant results are marked in bold. 
The highest quartile of AcAc adjusted for age, BMI, smoking and physical activity predicted 
conversion to T2D, OR 1.32 (95% CIs, 1.00, 1.74; P=0.047; Table 7), and also after further 
adjustment for FPG (OR 1.41, 95% CIs 1.06-1.89, P=0.019). Adjustment for 2hPG, instead of FPG, 
abolished statistical significance (P=0.423). When analyzed in the glucose tolerance categories, 
AcAc predicted incident diabetes in individuals with IFG (OR 1.49, 95% CI 1.12-1.99, P=0.007) 
after the adjustment for confounding factors.   
Additional adjustment for insulin sensitivity strengthened the association of KBs with 
development of hyperglycemia and conversion to T2D, whereas insulin secretion 
weakened/abolished these associations. 
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Association of risk SNPs for type 2 diabetes or hyperglycemia with the levels of ketone 
bodies 
After correction for multiple testing (threshold of statistical significance, P<4.0×10-4), the glucose 
increasing C allele of rs780094 of GCKR showed a significant association with elevated levels of 
BHB (effect size +5.6% per the C allele, P=3.7×10-6 after adjusting for age and BMI) and a 
nominally significant association with AcAc (+3.9%, P=0.003).  Additionally, there were 
nominally significant associations for SNPs of ANK1, GIPR, HMGA2, SLC2A2 and FADS1 with 
the levels of both AcAc and BHB. Also several other SNPs were nominally associated with 
either AcAc or BHB alone (Table 8). 
Table 8. Risk SNPs for type 2 diabetes or hyperglycemia associated (P<0.05) with fasting 
acetoacetate and β-hydroxybutyrate 
 
Gene 
 
SNP 
 Allele 
Risk 
allele Acetoacetate β-hydroxybutyrate 
N maj/min frequency %B P P* %B P P* 
ADAMTS9 
rs4607103 8120 C/T 74.1 -3.7 0.007 0.009 -3.3 0.067 0.079 
ANK1 
rs516946 8120 C/T 80.5 +3.4 0.042 0.036 +3.4 0.014 0.011 
CENTD2 
rs1552224 8119 A/C 74.7 1.9 0.022 0.025 1.8 0.099 0.133 
CRY2 
rs11605924 8108 A/C 52.9 1.7 0.124 0.097 3.4 0.002 0.001 
DGKB 
rs2191349 8120 G/T 42.8 1.3 0.152 0.160 2.3 0.038 0.047 
FADS1 
rs174550 8119 T/C 57.7 -3.2 6.7x10-4 5.5x10-4 -3.1 0.151 0.112 
FAM148B/C2CD4B, 
rs11071657 8118 A/G 69.1 -0.1 0.446 0.505 -2.7 0.032 0.019 
GCKR 
rs780094 8120 C/T 62.2 3.9 0.005 0.003 5.6 8.3x10-6 3.7x10-6 
GIPR 
rs10423928 8302 T/A 21.6 -3.8 0.001 0.001 -3.7 0.004 0.003 
HMGA2 
rs2612067 8353 T/G 6.90 -5.9 0.005 0.006 -6.0 0.009 0.010 
KCNQ1 
rs231362 8388 G/A 51.9 -1.8 0.050 0.041 -1.7 0.261 0.199 
KLF14 
rs972283 8120 G/A 57.5 -2.8 0.055 0.066 -2.7 0.009 0.014 
MC4R 
rs12970134 8120 G/A 17.5 -3.6 0.006 0.005 -2.0 0.129 0.100 
PPARG 
rs1801282 8119 C/G 84.9 3.0 0.036 0.037 
-
0.03 0.996 0.918 
SLC2A2 
rs11920090 8120 T/A 86.7 -3.8 0.011 0.011 -4.9 0.018 0.017 
 
Major/minor (maj/min) alleles of each SNP are shown. Risk alleles for hyperglycemia or T2D are 
underlined. Effect sizes (indicated as % of B from the mean) per risk allele. Significant P-values are 
given in bold (P<0.05) or bold and underlined (P< 4.0×10-4). P is unadjusted. P* is adjusted for age 
and BMI. Of 62 risk SNPs for T2D or hyperglycemia were studied, only SNPs that are associated with 
single or both traits presented in this table. 
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Gene expression of genes involved in ketone body metabolism 
Significant correlations were found with adipose tissue mRNA expression levels of several 
genes associated with ketolysis with glucose metabolism parameters (Table 9). Of these genes, 
ACAT1 expression had the most significant correlations with Glucose AUC (r=-0.314, P=6.1×10-
6), Matsuda ISI (r=0.479, P=7.1×10-13), and insulin secretion (r=-0.444, P=7.0×10-11). Similarly, the 
expressions of other genes regulating ketolysis, BDH1 (β-hydroxybutyrate dehydrogenase, type 
1), OXCT1 (3-oxoacid CoA transferase 1), and ACSS2 (acyl-CoA synthetase short-chain family 
member 2) were inversely correlated with Glucose AUC and insulin secretion and positively 
correlated with Matsuda ISI.  
Table 9. Pearson correlations of adipose tissue mRNA expression of major enzymes involved in fatty 
acid oxidation, ketogenesis and ketolysis with Glucose AUC, Matsuda ISI and Matsuda ISI- 
adjusted InsAUC0-30 /GlucAUC0-30 
Function /Gene 
Glucose AUC Matsuda ISI 
InsAUC0-30/ 
GlucAUC0-30 
r P r P r P 
Fatty acid 
oxidation 
      
CPT1A 0.198 4.9x10-3 -0.229 1.1x10-3 0.168 0.019 
CPT2 -0.068 0.340 0.249 3.7x10-4 -0.274 1.0x10-4 
Ketogenesis       
HMGCS2 0.078 0.273 -0.013 0.851 0.006 0.936 
HMGCS1 -0.042 0.557 0.088 0.217 -0.068 0.342 
Ketolysis       
BDH1 -0.222 1.6x10-3 0.425 3.4x10-10 -0.408 3.0x10-9 
OXCT1 -0.121 0.088 0.232 9.4x10-4 -0.182 0.011 
ACAT1 -0.314 6.1x10-6 0.479 7.1x10-13 -0.444 7.0x10-11 
ACSS2 -0.108 0.130 0.307 9.7x10-6 -0.274 1.0x10-4 
 
CPT1A, carnitine palmitoyltransferase 1A; CPT2, carnitine palmitoyltransferase II; HMGCS2, 3-
hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial); HMGCS1, 3-hydroxy-3-methylglutaryl-
CoA synthase 1 (soluble); BDH1, 3-hydroxybutyrate dehydrogenase, type 1; OXCT1, 3-oxoacid 
CoA transferase 1; ACAT1, acetyl-CoA acetyltransferase 1; ACSS2, acyl-CoA synthetase short-chain
family member 2. 
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6 Discussion 
6.1 REPRESENTATIVENESS OF THE STUDY POPULATION 
This study was based on a large population-based well-characterized METSIM cohort having a 
relatively long follow-up period (around 5 years) to ensure good statistical power. 
Studies I and III included a total of 9,398 non-diabetic men from the cross-sectional METSIM 
study examined in 2005-2010. Subjects, aged from 45 to 73 years, were randomly selected from 
the population register of the Kuopio town in Eastern Finland. In Study II, 1,346 non-diabetic 
men were selected randomly with equivocal percentages from each glucose category compared 
to the original METSIM cohort. All subjects included in Studies I-III had a 1-day outpatient visit 
to the Clinical Research Unit at the University of Eastern Finland, including an interview on 
their history of previous chronic diseases and current drug treatment, physical exercise, 
smoking, alcohol intake and cardiovascular risk factors. The diagnosis of T2D was based on an 
OGTT. Insulin sensitivity and insulin secretion were evaluated using validated OGTT-derived 
indices.  
Detailed phenotyping using the NMR method was applied to all individuals involved in 
METSIM study, and EMFAs were determined in a subset of the METSIM study population 
using gas chromatography. Measuring individual metabolites with these techniques carries a 
high potential in detecting and validating new biomarkers. All risk SNPs for 
hyperglycemia/T2D known at the time of the study were genotyped in the entire METSIM 
cohort, ensuring the identification of those SNPs associated with biomarkers of interest. 
Additional advantage of the METSIM study is that it includes a long-term follow-up (mean 
follow-up about 5 years), which permits an evaluation of the prospective significance of the 
identified biomarkers as predictors of worsening of hyperglycemia and incident T2D. The 
diagnosis of new diabetes was based on an OGTT. The main limitation of this series of studies is 
that the METSIM cohort includes only Finnish men and we did not have detailed dietary data 
which somewhat limits the conclusions drawn from Studies I-III. Study II, had a relatively small 
number of individuals who developed diabetes during the follow-up. Although the METSIM 
Study is large in size, the power was limited to detect genetic association with KB levels (Study 
III). 
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6.2 GLYCEROL AND FATTY ACIDS AS PREDICTORS OF HYPERGLYCEMIA 
AND INCIDENT TYPE 2 DIABETES (Study I) 
The phenotype represents both genetic predisposition and environmental influences, including 
diet, physical activity and smoking, and therefore assessing the concentration of different 
metabolites provides information on individual profile of physiological and pathophysiological 
markers. 
Glycerol is an important intermediate in glucose and lipid metabolism. Study I, revealed that 
fasting levels of glycerol and FFAs were higher not only in newly diagnosed diabetes but also in 
IFG and IGT in a cross-sectional analysis of the METSIM Study. Glycerol has a direct effect on 
glucose levels and gluconeogenesis and its levels have been shown to be elevated in obese 
individuals and in patients with type 2 diabetes (211, 220), highlighting the potential 
importance of glycerol homeostasis. We observed that fasting levels of glycerol, total TGs and 
FFAs predicted an increase in Glucose AUC and the development of new-onset T2D during this 
prospective 4.5-year follow-up of the METSIM cohort, independent of known risk factors for 
T2D. None of the previous studies have indicated glycerol to be a significant predictor of 
hyperglycemia and incident T2D. 
By measuring insulin sensitivity and insulin secretion with validated indices (217) we were able 
to evaluate statistically the possible mechanisms by which glycerol, total TGs and FFAs predict 
hyperglycemia and T2D. Our follow-up study of the METSIM cohort suggested for the first 
time that insulin resistance was the most important mediator for the association of levels of 
glycerol, total TGs and FFAs with the development of hyperglycemia. This conclusion is 
supported by our statistical evaluation revealing that adjustment for insulin sensitivity 
(Matsuda ISI) attenuated and/or abolished the association of glycerol, total TGs and FFAs with 
Glucose AUC and with incident T2D. High levels of glycerol and FFAs have been shown to 
increase insulin resistance in skeletal muscle (171). In contrast, adjustment for insulin secretion 
did not alter these associations, although previous studies have shown that long-term exposure 
of β-cells to FFAs can lead to impaired insulin secretion (172). 
Elevated levels of omega-3, omega-6 FAs, monounsaturated FAs, and saturated and omega-7 
and -9 FAs have been linked to hyperglycemia in some previous studies (179, 180, 185-187), 
although the evidence is conflicting. Human intervention trials have also provided somewhat 
contradictory results, but they suggest that saturated FAs induce insulin resistance (221). We 
demonstrated that the fasting levels of monounsaturated FAs, saturated FAs, and omega-7 and 
-9 FAs were increased in IFG, IGT and in newly diagnosed diabetes in this cross-sectional 
analysis of the METSIM cohort, whereas the levels of omega-3 and omega-6 FAs were reduced 
in individuals with newly diagnosed T2D. 
Monounsaturated FAs and saturated and omega-7 and -9 FAs predicted the worsening of 
hyperglycemia and the development of T2D in the METSIM cohort, independent of known risk 
factors for T2D. Three previous studies are in line with the present findings and have linked the 
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elevated risk of T2D with the levels of omega-7 FAs (palmitoleic acid) (185-187), but not with 
omega-9 FA (oleic acid).  Studies published on the association of omega-3 FAs and omega-6 FAs 
with incident T2D are somewhat conflicting and inconclusive (179, 180, 185). The present study 
detected a significant association of omega-6 FAs (mainly linoleic acid) with reduction in the 
development of both hyperglycemia and T2D. Linoleic acid is derived mainly from the diet, but 
it can be metabolized to longer chain unsaturated FAs. In the current study, the 
monounsaturated FAs, especially palmitoleic and oleic acids, were associated with an increased 
risk of abnormal glucose metabolism and T2D. This may be explained by the fact that the major 
saturated FAs are desaturated to monounsaturated FAs, and that in the Western diet, the levels 
of saturated FAs and monounsaturated FAs are positively correlated (222-224). 
To investigate the mechanisms underlying the associations of hyperglycemia with FAs, we 
evaluated their associations with insulin sensitivity and insulin secretion. We observed that 
insulin sensitivity was positively correlated with the levels of omega-6 FAs explaining at least in 
part the preventive effect of omega-6 FAs on the development of hyperglycemia and incident 
diabetes. In contrast, levels of monounsaturated FAs and saturated and omega-7 and -9 FAs 
showed negative correlations with insulin sensitivity, which is in agreement with previous 
findings of an inverse association of omega-7 FAs with insulin sensitivity (223, 225). Moreover, 
omega-9 FAs (dietary oleic acid) influence fat oxidation (226) suggesting that they may have 
negative effects on insulin sensitivity.  
Additional evidence that insulin resistance is a potent mediator for the association of omega 
FAs with hyperglycemia emerges from our multivariate models. The adjustment for Matsuda 
ISI, but not for insulin secretion, attenuated the associations of omega-6 FAs (including linoleic 
acid), monounsaturated FAs and saturated FAs, and omega-7 and -9 FAs with Glucose AUC 
and incident T2D. These results might imply that insulin sensitivity is the major causal 
mechanism explaining the association of these FAs with hyperglycemia and the risk of incident 
T2D.  Similarly, the preventive effect of omega-6 FAs was mediated via high insulin sensitivity. 
FAs are important structural components of cell membranes, and they are precursors of long 
chain FA derived molecules, which may affect insulin sensitivity. Furthermore, FAs modify 
gene expression and receptor binding (227), thus making them an important candidate in the 
search of risk factors for T2D and related glucose abnormalities.  
In summary, Study I suggested that high levels of glycerol, FFAs, serum monounsaturated FAs, 
saturated FAs, and omega-7 and -9 FAs are not only indicators of diabetic hyperglycemia but 
are also markers of disturbed glucose metabolism in the prediabetic state. However, this study 
does not necessarily imply that insulin resistance is a causal mechanism linking elevated levels 
of glycerol and FAs with the worsening of hyperglycemia and incident T2D, since dietary and 
other factors could also play an important role in these associations. 
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6.3 ERYTHROCYTE MEMBRANE FATTY ACIDS AS PREDICTORS OF 
HYPERGLYCEMIA AND INCIDENT TYPE 2 DIABETES (Study II) 
Previous studies have not investigated the association of EMFA proportions and their product 
to precursor ratios with hyperglycemia. This present cross-sectional analysis of the METSIM 
cohort demonstrated that the levels of palmitoleic acid (C16:1n-7), SCD1 (16:1n-7/16:0) and D6D 
(20:3n-6/18:2n-6) were significantly higher not only in individuals with newly diagnosed T2D 
but also in individuals with IFG, IGT and both. In contrast, linoleic acid (C18:2n-6) was 
significantly lower in newly diagnosed T2D.  
In our prospective follow-up study, high levels of palmitoleic acid, dihomo-gamma-linolenic 
acid and the ratios of 16:1n-7/16:0 (SCD1 activity) and 20:3n-6/18:2n-6 (D6D activity) 
significantly predicted the worsening of hyperglycemia, whereas linoleic acid and the 18:1n-
7/16:1n-7 ratio (elongase activity) predicted a decrease in Glucose AUC at follow-up. Moreover, 
palmitoleic acid and the 16:1n-7/16:0 ratio (SCD1 activity) nominally increased the risk of 
incident T2D, independent of known confounding factors, whereas linoleic acid was preventive 
of diabetes. Our conclusions are in line with three previously published longitudinal studies 
(181, 202, 203). The ratios of 20:3n-6/18:2n-6 (D6D activity) and 18:1n-7/16:1n-7 (elongase 
activity) predicted incident T2D in our study, but these associations were abolished after 
adjusting for confounding factors. In contrast, the levels of n-3 polyunsaturated FAs were not 
associated with the worsening of glycemia or the risk of diabetes, in line with a recent meta-
analysis (228).  
We also evaluated the role of insulin sensitivity and insulin secretion as potential mediators for 
the associations of EMFAs proportions and their ratios with incident T2D.  Previous studies 
have hinted that the FA composition especially in skeletal muscle could alter membrane 
fluidity, ion permeability, and insulin receptor binding and affinity, or insulin action (184, 227). 
Cross-sectional studies have reported that the altered D5D and D6D activities could be related 
to insulin resistance (177, 229). In our study, adjustment for insulin sensitivity somewhat 
weakened P values but did not abolish statistical significance. Similarly, adjustment for insulin 
secretion did not essentially change these results suggesting that the role of genes could be 
important in these associations. However, the ratios of 20:3n-6/18:2n-6 (D6D activity) and 16:1n-
7/16:0 (SCD1 activity) which were associated with abnormal glucose tolerance at baseline, also 
predicted decreases in insulin sensitivity and insulin secretion at the follow-up study. 
Therefore, EMFAs may decrease insulin sensitivity and insulin secretion, although it is not 
possible to conclude the direction of causality because dietary and other factors can also 
influence insulin sensitivity. 
6.4 KETONE BODY LEVELS AS PREDICTORS OF HYPERGLYCEMIA AND 
INCIDENT TYPE 2 DIABETES (Study III) 
High levels of KBs are a characteristic finding in individuals with diabetes (230), but there is a 
lack of information about the KB levels in the non-diabetic glucose range. We observed an 
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increase in KB levels with increasing glucose levels in an OGTT in a cross-sectional analysis of 
the METSIM study cohort. These results agree with a previous finding indicating that elevated 
glucose levels are associated with increased levels of KBs (211).  
In the prospective analysis of the METSIM cohort we observed that the levels of AcAc and BHB 
significantly predicted the worsening of hyperglycemia in non-diabetic individuals, but these 
associations were abolished after adjustment for Glucose AUC at baseline.  This could point to 
an important link between the levels of KBs and glucose metabolism. AcAc, but not BHB, 
predicted the development of new T2D in our prospective follow-up of the METSIM cohort, 
independent of known risk factors for T2D. The reason why KBs predicted very significantly 
the worsening of glycemia, but not so clearly incident T2D, are FPG and 2hPG levels at the 
diagnosis of T2D which were often only marginally elevated (FPG in the range of 7.0-7.5 
mmol/L, 2hPG in the range of 11.1-12.0 mmol/L), whereas the levels of KBs were significantly 
increased at higher glucose levels (FPG levels exceeding 8.0 mmol/L, and 2hPG levels exceeding 
12.0 mmol/L, Figure 8).  
To study the mechanisms by which KBs increase the risk of hyperglycemia and T2D, we 
investigated the association of KB levels with insulin sensitivity and insulin secretion. 
Surprisingly, we found that high levels of KBs were associated with high insulin sensitivity in 
the non-diabetic glucose range at baseline, similar to recent findings in young Finnish adults 
(210). Furthermore, it was noted that insulin sensitivity was significantly correlated with the 
key enzymes of ketolysis, which suggests that in insulin sensitive individuals KBs are rapidly 
converted to acetyl-CoA, which stimulates oxidative phosphorylation and mitochondrial 
generation of ATP. However, it is not likely that insulin resistance is an important mechanism 
in the prediction of hyperglycemia by elevated KB levels. This was clearly demonstrated by our 
METSIM follow-up data which showed that adjustment for Matsuda ISI did not weaken the 
association of KBs with the development of hyperglycemia. In contrast, including a marker of 
insulin secretion in the model substantially weakened or abolished the association of KBs with 
the development of hyperglycemia and the conversion to T2D. These findings emphasize the 
crucial role of impaired insulin secretion as a regulator of hyperglycemic effects of KBs. 
Adequate insulin secretion relative to insulin sensitivity maintains low levels of KBs by 
suppressing the expression of hormone sensitive lipase and thus prevents the release of FFAs 
from adipose tissue which is the major source of hepatic ketogenesis and high circulating levels 
of KBs (206, 231). 
We also investigated the association of risk SNPs for hyperglycemia and T2D with KB levels. Of 
the 62 SNPs analyzed, only the glucose increasing major C allele of rs780094 of GCKR (encoding 
glucokinase regulatory protein) was significantly associated with increased BHB levels and 
nominally associated with AcAc levels. Glucokinase (GCK) is ‘a sensor’ of the glucose level 
which plays a crucial role in whole body glucose homeostasis.  The activity of GCK is regulated 
by GCKR in the liver (141). The C allele of rs780094 of GCKR has been previously reported to be 
associated with fasting glycemia, risk of T2D, insulin resistance, and decreased levels of total 
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and VLDL, TGs, decreased levels of alanine and isoleucine, and elevated levels of glutamine 
(62, 142, 161, 232, 233). The significant association of rs780094 with KB levels adds further to the 
pleiotropic effects of GCKR. 
 
6.5 CONCLUDING REMARKS 
There is still a lack of reliable biomarkers for the detection of the metabolic alterations 
associated with T2D highlighting the need for the development of early diagnostic and 
prognostic markers for T2D. A detailed understanding of the pathophysiology of T2D and 
identification of early metabolic alterations is essential for identifying individuals at high risk of 
this disease. Recent advancements in the application of high throughput methodologies, 
including deep metabolic phenotyping and genotyping in a large, well powered and 
characterized population cohorts has made possible the rapid progress in the field of biomarker 
discovery.  
Previous studies and recent studies based on the application of metabolomics have identified 
several biomarkers predicting incident T2D including total TGs, HDL cholesterol, inflammatory 
markers, adiponectin, liver enzymes, fetuin-A, aromatic amino acids  and branch-chain amino 
acids which have been measured from biofluids or tissue samples (151). In the present studies, 
NMR and gas chromatography were utilized and the analysis revealed that levels of glycerol, 
serum FAs, proportions of EMFAs and KBs can be considered as biomarkers for the 
development of hyperglycemia and incident T2D. However, the clinical importance of these 
biomarkers needs to be validated in other populations and also in women.   
Our series of studies show that it is possible to obtain important information on the 
mechanisms how different metabolites can impair glucose tolerance and further to incident T2D 
if reliable markers of insulin sensitivity and insulin secretion are applied. It is important to 
measure both of these pathophysiological abnormalities since the mechanisms by which an 
individual metabolite increases the risk of hyperglycemia and T2D are likely to differ. For 
example, insulin resistance seems to be a more likely causal mechanism how high 
concentrations of certain serum FAs increase the risk of T2D, whereas impaired insulin 
secretion is likely to be a causal mechanism how KBs lead to the worsening of hyperglycemia 
and elevated risk of T2D. However, several other factors are likely to play also a significant role 
in these associations, namely dietary factors and gene variants.  
GWAs and meta-analyses have uncovered several novel risk loci for T2D that are consistent 
across all ethnic groups. Revealing biological functions of these common variants has been 
challenging. Recently exome sequencing has accelerated the potential to identify new low-
frequency and rare variants in complex diseases, including T2D. However even taking the 
applications of exome sequencing and exome chip into account, studies on the genetics of T2D 
need other approaches. Gene-gene and gene-environment/lifestyle interaction analyses are 
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urgently needed as well as studies on epigenetics (methylation of promoters and histone 
modifications).   
In conclusion, we have identified novel biomarkers for the estimation of the risk for the 
development of hyperglycemia and incident diabetes beyond classical clinical indicators and 
laboratory measurements. Our findings indicate that plasma metabolites predict the onset of 
T2D and provide important information beyond standard clinical markers.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
7 Summary 
 
The main findings of Studies I – III were as follows: 
Study I: High fasting levels of glycerol, FFAs, monounsaturated FAs, and saturated FAs, and 
omega-7 and -9 FAs predicted the worsening of hyperglycemia and incident type 2 diabetes, 
whereas high levels of omega-6 FAs were associated with a reduced risk of hyperglycemia and 
type 2 diabetes.  Insulin resistance explained these associations, at least in part. 
Study II: High levels of palmitoleic acid, dihomo-gamma-linolenic acid, 16:1n-7/16:0 and 20:3n-
6/18:2n-6 ratios predicted the worsening of hyperglycemia, whereas linoleic acid and 18:1n-
7/16:1n-7 ratio predicted the improvement of hyperglycemia. The high levels of palmitoleic acid 
and 16:1n-7/16:0 nominally predicted incident type 2 diabetes, whereas linoleic acid prevented 
type 2 diabetes. These associations were largely independent of insulin sensitivity, insulin 
secretion and glucose levels. 
Study III: High levels of acetoacetate and β-hydroxybutyrate predicted the worsening of 
hyperglycemia, and acetoacetate predicted incident type 2 diabetes. Impaired insulin secretion, 
but not insulin resistance, explained these associations. One common variant of GCKR was 
significantly associated with β-hydroxybutyrate levels.  
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The early diagnosis of diabetes is 
important in order to avoid long-
term micro- and macrovascular 
complications in individuals at high 
risk of type 2 diabetes. This thesis 
aims to investigate the association 
of various metabolic and genetic 
biomarkers with hyperglycemia 
and type 2 diabetes. Several novel 
biomarkers were identified in this 
study as predictors of hyperglycemia 
and incident type 2 diabetes.
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